US20180092933A1 - Small molecule enhancer for dendritic cell cancer vaccines - Google Patents
Small molecule enhancer for dendritic cell cancer vaccines Download PDFInfo
- Publication number
- US20180092933A1 US20180092933A1 US15/817,754 US201715817754A US2018092933A1 US 20180092933 A1 US20180092933 A1 US 20180092933A1 US 201715817754 A US201715817754 A US 201715817754A US 2018092933 A1 US2018092933 A1 US 2018092933A1
- Authority
- US
- United States
- Prior art keywords
- cancer
- compound
- mammal
- tumors
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000009566 cancer vaccine Methods 0.000 title description 6
- 229940022399 cancer vaccine Drugs 0.000 title description 6
- 210000004443 dendritic cell Anatomy 0.000 title description 3
- 150000003384 small molecules Chemical class 0.000 title description 2
- 239000003623 enhancer Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 141
- 238000000034 method Methods 0.000 claims abstract description 120
- 150000001875 compounds Chemical class 0.000 claims abstract description 91
- 241000124008 Mammalia Species 0.000 claims abstract description 52
- 201000011510 cancer Diseases 0.000 claims abstract description 50
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 38
- 102000004127 Cytokines Human genes 0.000 claims abstract description 36
- 108090000695 Cytokines Proteins 0.000 claims abstract description 36
- 108010022999 Serine Proteases Proteins 0.000 claims abstract description 33
- 102000012479 Serine Proteases Human genes 0.000 claims abstract description 33
- 230000001965 increasing effect Effects 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 20
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 230000005809 anti-tumor immunity Effects 0.000 claims abstract description 11
- 230000002159 abnormal effect Effects 0.000 claims abstract description 10
- 230000002708 enhancing effect Effects 0.000 claims abstract description 10
- 230000004936 stimulating effect Effects 0.000 claims abstract description 9
- 230000004663 cell proliferation Effects 0.000 claims abstract description 8
- 230000014564 chemokine production Effects 0.000 claims abstract description 5
- 230000016396 cytokine production Effects 0.000 claims abstract description 5
- FKCMADOPPWWGNZ-YUMQZZPRSA-N [(2r)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O FKCMADOPPWWGNZ-YUMQZZPRSA-N 0.000 claims description 94
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 39
- 229960005395 cetuximab Drugs 0.000 claims description 30
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 108010050095 PT-100 dipeptide Proteins 0.000 claims description 22
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims description 21
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 21
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 16
- 238000002512 chemotherapy Methods 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 15
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 12
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 10
- 229940029030 dendritic cell vaccine Drugs 0.000 claims description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 9
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 9
- 210000000987 immune system Anatomy 0.000 claims description 9
- -1 interferon-αn3 Proteins 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 230000003211 malignant effect Effects 0.000 claims description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 229910052796 boron Inorganic materials 0.000 claims description 6
- 230000002209 hydrophobic effect Effects 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 239000007909 solid dosage form Substances 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 5
- WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims description 4
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 4
- 229960004395 bleomycin sulfate Drugs 0.000 claims description 4
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 231100000371 dose-limiting toxicity Toxicity 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- 229960005144 gemcitabine hydrochloride Drugs 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000037841 lung tumor Diseases 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- BKBBTCORRZMASO-ZOWNYOTGSA-M methotrexate monosodium Chemical compound [Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C([O-])=O)C=C1 BKBBTCORRZMASO-ZOWNYOTGSA-M 0.000 claims description 4
- 229960003058 methotrexate sodium Drugs 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 4
- 208000023958 prostate neoplasm Diseases 0.000 claims description 4
- 239000003207 proteasome inhibitor Substances 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 229940063683 taxotere Drugs 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 claims description 4
- 229960004982 vinblastine sulfate Drugs 0.000 claims description 4
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims description 4
- 229960002110 vincristine sulfate Drugs 0.000 claims description 4
- 125000006691 (C2-C7) heterocyclyl group Chemical group 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 206010070308 Refractory cancer Diseases 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 claims description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000000623 heterocyclic group Chemical group 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000001165 hydrophobic group Chemical group 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- 150000007970 thio esters Chemical class 0.000 claims description 3
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 claims description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003862 vemurafenib Drugs 0.000 claims description 3
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 claims description 2
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 claims description 2
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 2
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 108010024976 Asparaginase Proteins 0.000 claims description 2
- 102000015790 Asparaginase Human genes 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 241000282465 Canis Species 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000009458 Carcinoma in Situ Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 241000282324 Felis Species 0.000 claims description 2
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 102100040019 Interferon alpha-1/13 Human genes 0.000 claims description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- 206010029098 Neoplasm skin Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 241000288906 Primates Species 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 108700025316 aldesleukin Proteins 0.000 claims description 2
- 229960005310 aldesleukin Drugs 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 229960003272 asparaginase Drugs 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004630 chlorambucil Drugs 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 229960002436 cladribine Drugs 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960000684 cytarabine Drugs 0.000 claims description 2
- 229960003901 dacarbazine Drugs 0.000 claims description 2
- 229960000640 dactinomycin Drugs 0.000 claims description 2
- 229960003109 daunorubicin hydrochloride Drugs 0.000 claims description 2
- 229960003265 epirubicin hydrochloride Drugs 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960000752 etoposide phosphate Drugs 0.000 claims description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 2
- 229960000961 floxuridine Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 229960001176 idarubicin hydrochloride Drugs 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229940047124 interferons Drugs 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000004962 larynx cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 229960002868 mechlorethamine hydrochloride Drugs 0.000 claims description 2
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 229960001924 melphalan Drugs 0.000 claims description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- 229960001156 mitoxantrone Drugs 0.000 claims description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000005443 oral cavity cancer Diseases 0.000 claims description 2
- 229960001744 pegaspargase Drugs 0.000 claims description 2
- 108010001564 pegaspargase Proteins 0.000 claims description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 2
- 229960002340 pentostatin Drugs 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 229940083542 sodium Drugs 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000013076 thyroid tumor Diseases 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 229960002190 topotecan hydrochloride Drugs 0.000 claims description 2
- 208000025421 tumor of uterus Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 229960002166 vinorelbine tartrate Drugs 0.000 claims description 2
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 claims description 2
- 108010059568 ARI-4175 Proteins 0.000 description 112
- 108010009573 talabostat Proteins 0.000 description 70
- 241000699670 Mus sp. Species 0.000 description 58
- 238000011282 treatment Methods 0.000 description 22
- 102000019034 Chemokines Human genes 0.000 description 16
- 108010012236 Chemokines Proteins 0.000 description 16
- 230000001988 toxicity Effects 0.000 description 16
- 231100000419 toxicity Toxicity 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 238000011740 C57BL/6 mouse Methods 0.000 description 14
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 13
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 231100000682 maximum tolerated dose Toxicity 0.000 description 12
- 230000004044 response Effects 0.000 description 11
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- WDFZXMUIFGGBQF-WDSKDSINSA-N [(2r)-1-[(2s)-2-aminopropanoyl]pyrrolidin-2-yl]boronic acid Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1B(O)O WDFZXMUIFGGBQF-WDSKDSINSA-N 0.000 description 6
- 108010050055 alanylpyrrolidine-boronic acid Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- 108010016626 Dipeptides Proteins 0.000 description 4
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 238000003305 oral gavage Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- KVMHGXYFIRJLAX-UHFFFAOYSA-N C#[N+]C Chemical compound C#[N+]C KVMHGXYFIRJLAX-UHFFFAOYSA-N 0.000 description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 3
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 102100036968 Dipeptidyl peptidase 8 Human genes 0.000 description 3
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 3
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 101710113436 GTPase KRas Proteins 0.000 description 3
- 101000804947 Homo sapiens Dipeptidyl peptidase 8 Proteins 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 206010069755 K-ras gene mutation Diseases 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 0 [1*]C.[2*]C(N)C(=O)N1CCCC1C Chemical compound [1*]C.[2*]C(N)C(=O)N1CCCC1C 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000011284 combination treatment Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000006054 immunological memory Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 231100001231 less toxic Toxicity 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 229940034080 provenge Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- LRFZIPCTFBPFLX-SSDOTTSWSA-N (2s)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C(C)(C)C LRFZIPCTFBPFLX-SSDOTTSWSA-N 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000013816 Cytotoxic T-lymphocyte antigen 4 Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 108010066823 proline dipeptidase Proteins 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229950010637 talabostat Drugs 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 239000012646 vaccine adjuvant Substances 0.000 description 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- JTMMMUATVXYDKD-RISBUOFLSA-N CC(C)(C)OC(=O)N[C@H](C(=O)N1CCC[C@H]1N1O[C@@H]2CC3CC(C3(C)C)[C@]2(C)O1)C(C)(C)C.CC(C)(C)[C@H](N)C(=O)N1CCC[C@H]1N(O)O.CC1(C)C2CC1[C@]1(C)ON([C@@H]3CCCN3)O[C@@H]1C2.Cl.Cl Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)N1CCC[C@H]1N1O[C@@H]2CC3CC(C3(C)C)[C@]2(C)O1)C(C)(C)C.CC(C)(C)[C@H](N)C(=O)N1CCC[C@H]1N(O)O.CC1(C)C2CC1[C@]1(C)ON([C@@H]3CCCN3)O[C@@H]1C2.Cl.Cl JTMMMUATVXYDKD-RISBUOFLSA-N 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 101710087084 Dipeptidyl peptidase 2 Proteins 0.000 description 1
- 102100036969 Dipeptidyl peptidase 9 Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000804945 Homo sapiens Dipeptidyl peptidase 9 Proteins 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101100449533 Mus musculus Cxcl1 gene Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- BZTBBVKEKPNNBE-YFKPBYRVSA-N [(2r)-1-(2-aminoacetyl)pyrrolidin-2-yl]boronic acid Chemical compound NCC(=O)N1CCC[C@H]1B(O)O BZTBBVKEKPNNBE-YFKPBYRVSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 101150042537 dld1 gene Proteins 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- Cancer is America's second leading cause of death. Approved anticancer agents, both chemotherapeutic and targeted agents, are limited by toxicity and are ultimately ineffective against solid tumors, e.g.: lung, colorectal, breast, pancreatic, and prostate cancers, which account for more than 85% of cancer deaths.
- Val-boroPro also known as PT-100 or talabostat, is a dipeptide boronic acid that showed remarkable efficacy in shrinking tumors in mice through immune activation.
- PT-100 or talabostat is a dipeptide boronic acid that showed remarkable efficacy in shrinking tumors in mice through immune activation.
- One aspect of the present invention relates to a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the invention relates to a method of increasing antitumor immunity in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the invention relates to a method of stimulating or enhancing an immune response in a mammal, comprising administering to a mammal in need of an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Yet another aspect of the invention relates to a method of treating a condition characterized by abnormal cell proliferation, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the invention relates to a method of increasing cytokine and chemokine production in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the invention relates to a method of stimulating or enhancing production of T-cells in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases, wherein said T cells recognize an antigen on a malignant cell.
- the invention relates to any one of the methods described above, wherein the compound is represented by Formula I:
- X is B(Y 1 )(Y 2 ) or CN;
- Y 1 and Y 2 are independently OH, or together with the boron atom to which they are attached represent a group that is hydrolysable to a boronic acid, or together with the boron atom to which they are attached form a 5- to 8-membered ring that is hydrolysable to a boronic acid;
- R 1 is selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkynyl, carbonyl, carboxyl, ester, formate, ketone, thiocarbonyl, thioester, thioacetate, thioformate, amino, acylamino, amido, nitro, sulfate, sulfonate, sulfonamido, —(CH 2 ) m —R 7 , —(CH 2 ) m —OH, —(CH 2 ) m —O-lower alkyl, —(CH 2 ) m —O-lower alkenyl, —(CH 2 ) n —O—(CH 2 ) m —R 7 , —(CH 2 ) m —SH, —(CH 2 ) m —S-lower alkyl, —(CH 2 ) m —S-lower alkeny
- R 7 represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle;
- R 8 independently represents hydrogen, —CH 3 , or —(CH 2 ) n —CH 3 ;
- n 0, 1, 2, 3, 4, 5, or 6;
- R 2 is a hydrophobic group selected from the group consisting of n-propyl, C 4 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 2 -C 7 heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and side chains of naturally occurring hydrophobic amino acids;
- n 0, 1, or 2;
- q 0, 1, 2, 3, or 4.
- the invention relates to any one of the methods described above, wherein the compound is t-butylGly-boroPro.
- FIG. 1 shows that Ala-boroPro (A-bP) and Val-boroPro (V-bP) both inhibit prolyl oligoproteases, but Ala-boroPro does not stimulate the immune system.
- Val-boroPro is a potent immune stimulator.
- FIG. 2 shows that PT-100 produces complete regression of early stage tumors but not of established tumors.
- FIG. 3 shows that PT-100+Dendritic Cell (DC) vaccine produces regression of established tumors.
- FIG. 4 shows that Val-boroPro (2054 in the figure), but not Ala-boroPro (2054 in the figure), stimulates G-CSF and CXCL1/KC in BALB/c mice.
- G-CSF and CXL1/KC are markers of anti-cancer immune enhancing activity. The experimental setup and results are discussed in Example 3.
- FIG. 5 shows that Ari-4175 (4175-2 in the figure) is a very potent inducer of cytokines in vivo.
- the experimental setup and results are discussed in Example 3.
- FIG. 6 shows that ARI-4175 (4175-2) is much more potent than PT-100 (2054) at inducing G-CSF and CXCL1 cytokines, which are markers of anti-cancer immune-enhancing activity.
- the experimental setup and results are discussed in Example 3.
- FIG. 7 shows that ARI-4175 establishes immunity to tumor rechallenge in the M3-9-M RMS model. The experimental setup and results are discussed in Example 4.
- FIG. 8A shows that ARI-4175 increases potency of a DC vaccine in a rhabdomyosarcoma (RMS) model to inhibit growth of established RMS.
- RMS rhabdomyosarcoma
- FIG. 8B shows that ARI-4175 increases mouse survival in a rhabdomyosarcoma (RMS) model.
- RMS rhabdomyosarcoma
- FIG. 9 shows tumor growth in individual mice in the experiment described in Experiment 1.
- FIG. 10 shows that ARI-4175 (4175) does not exhibit significant in vitro activity against colorectal cancer cell lines. There is also no activity when 4175 is combined with cetuximab (CTX). This is expected, since the antitumor effects of ARI-4175 and cetuximab are thought to be mediated through antibody-dependent cell-mediated cytotoxicity (ADCC).
- ADCC antibody-dependent cell-mediated cytotoxicity
- FIG. 11 shows that CD16 expression is upregulated on NK cells taken from nude mice treated with ARI-4175.
- FIG. 12 shows that LAMP-1 (CD107) expression is upregulated on NK cells taken from nude mice treated with ARI-4175.
- FIG. 13A shows the in vivo inhibition by ARI-4175 of colon cancer xenografts.
- the figure shows the inhibition of DLD1 xenografts by ARI-4175 alone or in combination with cetuximab (CTX).
- CTX cetuximab
- FIG. 13B shows the in vivo inhibition by ARI-4175 of colon cancer xenografts.
- the figure shows the inhibition of HCT-116 by ARI-4175 alone or in combination with cetuximab (CTX).
- CTX cetuximab
- FIG. 14 shows that cytotoxicity of splenocytes from C57BI/6 non-tumor-bearing mice treated with ARI-4175 and/or cetuximab (CTX) is enhanced against HCT116 tumor cells.
- CTX cetuximab
- FIG. 15 shows that ARI-4175 induces CD69 on human NK cells.
- the results shown are with cultured human PBLs from two healthy donors after a 1 day incubation.
- FIG. 16 shows that ARI-4175 is as effective as PT-100 but less toxic at a high dose.
- FIG. 17A shows that as adjuvant to tumor-primed T cell transfer, ARI-4175 induces tumor regression in late treatment RMS M3-9-M model.
- FIG. 17B shows that as adjuvant to tumor-primed T cell transfer, ARI-4175 induces tumor regression in late treatment RMS M3-9-M model.
- FIG. 18A shows that combination treatment with ARI-4175 and adoptive T cell transfer in Rag1 ⁇ / ⁇ recipients significantly reduces RMS M3-9-M volume: Female Rag1 ⁇ / ⁇ mice received na ⁇ ve or RMS-primed T cells one day after tumor challenge.
- FIG. 19A shows that ARI-4175 is a potent adjuvant to DC vaccination as evidenced by significantly improved survival and reduced RMS M3-9-M volume.
- the figure shows a late treatment model for DC vaccination and ARI-4175 treatment.
- FIG. 19B shows that ARI-4175 is a potent adjuvant to DC vaccination as evidenced by significantly improved survival and reduced RMS M3-9-M volume.
- the figure shows the tumor volume curve (mean ⁇ S.D.) and survival curve.
- FIG. 20 shows the results of a maximum tolerated dose (MTD) study using SD rats with the data taken 30 minutes post-dose.
- MTD maximum tolerated dose
- FIG. 21 shows a dose-plasma response curve for PT-100 and ARI-4175.
- FIG. 22 shows pharmacokinetic data for the open vs. closed forms of ARI-4175.
- ARI-4175 exists in an open, or linear, form; under neutral or basic conditions, a closed, cyclized form is highly favored.
- FIG. 23 shows tumor growth in individual mice in the RMS model.
- One aspect of the present invention relates to a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the present invention relates to a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases, wherein the compound is not Val-boroPro.
- Another aspect of the present invention relates to any one of the foregoing methods, wherein said compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- cancer is selected from the group consisting of basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, CNS cancer, colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, intra-epithelial neoplasm, kidney cancer, larynx cancer, leukemia, acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, melanoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer,
- the cancer is selected from the group consisting of prostate cancer, colorectal cancer, multiple myeloma, and non-small cell lung cancer.
- the cancer is selected from lung cancer, colorectal cancer, breast cancer, pancreatic cancer and prostate cancer.
- the cancer is lung cancer.
- the cancer is non-small cell lung cancer.
- the cancer is colorectal cancer.
- the cancer is breast cancer.
- the cancer is pancreatic cancer.
- the cancer is prostate cancer.
- the cancer is metastatic.
- Another aspect of the invention relates to any one of the methods described above, further comprising co-administering to the mammal a therapeutically effective amount of tumor-primed T-cells.
- the tumor-primed T-cells are administered prior to the administration of the compound.
- the tumor-primed T-cells are administered subsequent to the administration of the compound.
- the tumor-primed T-cells are administered concurrently with administration of the compound.
- Another aspect of the invention relates to any one of the methods described above, further comprising co-administering to the mammal a therapeutically effective amount of an orally active tumor antigen.
- Yet another aspect of the invention relates to any one of the methods described above, further comprising co-administering to the mammal a therapeutically effective amount of a dendritic cell vaccine.
- Still another aspect of the invention relates to any one of the methods described above, further comprising administration of an adjuvant.
- Another aspect of the present invention relates to any one of the aforementioned embodiments, further comprising treating the mammal with a second therapy selected from the group consisting of surgery, radiation and chemotherapy.
- the second therapy is surgery.
- the second therapy is radiation.
- the second therapy is chemotherapy.
- the chemotherapy is selected from the group consisting of of ipilimumab, vemurafenib, GDC-0879, PLX-4720, aldesleukin, asparaginase, bleomycin sulfate, carboplatin, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin hydrochloride, docetaxel, doxorubicin, doxorubicin hydrochloride, epirubicin hydrochloride, etoposide, etoposide phosphate, floxuridine, fludarabine, fluorouracil, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, interferons, interferon- ⁇ 2a, interferon- ⁇ 2b, interferon-
- the chemotherapy is selected from the group consisting of bleomycin sulfate, carboplatin, cisplatin, docetaxel, doxorubicin, doxorubicin hydrochloride, fluorouracil, gemcitabine, gemcitabine hydrochloride, methotrexate, methotrexate sodium, paclitaxel, taxol, taxotere, vinblastine sulfate and vincristine sulfate.
- the chemotherapy is a dipeptidylpeptidase IV inhibitor.
- the chemotherapy is a FAP-activated chemotherapeutic, a FAP-activated dipeptidylpeptidase IV inhibitor, or a FAP-activated proteasome inhibitor.
- the chemotherapy is a FAP-activated proteasome inhibitor.
- the antibody is selected from the group consisting of trastuzamab, cetuximab, bevacizumab, and rituximab.
- One aspect of the present invention relates to a method of increasing antitumor immunity in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- the compound is not Val-boroPro.
- the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- the antitumor immunity is increased for tumors selected from the group consisting of lung tumors, lymphomas, breast tumors, colorectal tumors, thyroid tumors, uterine tumors, pancreatic tumors, prostate tumors, skin tumors, kidney tumors, liver tumors and brain tumors.
- the antitumor immunity is increased for tumors selected from the group consisting of lung tumors, breast tumors, colorectal tumors, pancreatic tumors and prostate tumors.
- the antitumor immunity comprises antibody-dependent cell-mediated cytotoxicity.
- Another aspect of the invention relates to a method of stimulating or enhancing an immune response in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- the compound is not Val-boroPro.
- the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- the immune response is stimulated.
- the immune response is enhanced.
- the immune response comprises antibody-dependent cell-mediated cytotoxicity.
- the mammal has cancer or is at risk of developing cancer.
- the mammal is in remission of cancer.
- the mammal has a refractory or resistant cancer.
- Another aspect of the invention relates to a method of treating a condition characterized by abnormal cell proliferation, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- the compound is not Val-boroPro.
- the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- the abnormal cell proliferation is cancer, a blood vessel proliferative disorder or a fibrotic disorder.
- the abnormal cell proliferation is abnormal angiogenesis.
- Another aspect of the invention relates to a method of increasing cytokine and/or chemokine production in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- the compound is not Val-boroPro.
- the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- Another aspect of the invention relates to a method of stimulating or enhancing production of T-cells in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases, wherein said T-cells recognize an antigen on a malignant cell.
- the compound is not Val-boroPro.
- the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- the production of T-cells is stimulated.
- the production of T-cells is enhanced.
- the malignant cell is a carcinoma, sarcoma, leukemia, lymphoma or myeloma.
- the mammal is a primate, canine, equine, feline or bovine.
- the mammal is a human.
- the compound is administered orally or parenterally.
- the compound is administered parenterally.
- the compound is administered orally.
- the compound is administered in a solid dosage form.
- the solid dosage form is a tablet, capsule or pill.
- the solid dosage form is a tablet.
- the compound is administered in an amount sufficient to stimulate the immune system without dose limiting toxicity.
- the invention relates to any one of the methods described above, wherein the compound is represented by Formula I:
- X is B(Y 1 )(Y 2 ) or CN;
- Y 1 and Y 2 are independently OH, or together with the boron atom to which they are attached represent a group that is hydrolysable to a boronic acid, or together with the boron atom to which they are attached form a 5- to 8-membered ring that is hydrolysable to a boronic acid;
- R 1 is selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkynyl, carbonyl, carboxyl, ester, formate, ketone, thiocarbonyl, thioester, thioacetate, thioformate, amino, acylamino, amido, nitro, sulfate, sulfonate, sulfonamido, —(CH 2 ) m —R 7 , —(CH 2 ) m —OH, —(CH 2 ) m —O-lower alkyl, —(CH 2 ) m —O-lower alkenyl, —(CH 2 ) n —O—(CH 2 ) m —R 7 , —(CH 2 ) m —SH, —(CH 2 ) m —S-lower alkyl, —(CH 2 ) m —S-lower alkeny
- R 7 represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle;
- R 8 independently represents hydrogen, —CH 3 , or —(CH 2 ) n —CH 3 ;
- n 0, 1, 2, 3, 4, 5, or 6;
- R 2 is a hydrophobic group selected from the group consisting of n-propyl, C 4 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, C 2 -C 7 heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and side chains of naturally occurring hydrophobic amino acids;
- n 0, 1, or 2;
- q 0, 1, 2, 3, or 4.
- q is 0, 1, or 2.
- q is 0.
- n 0.
- n 1
- n is 2.
- X is B(Y 1 )(Y 2 ).
- X is B(OH) 2 .
- R 2 is selected from the group consisting of t-butyl, isobutyl, pentyl, cyclohexyl, benzyl, or naphthyl.
- R 2 is selected from the group consisting of t-butyl, isobutyl, or pentyl.
- R 2 is t-butyl
- R 2 is the side chain of a naturally occurring hydrophobic amino acid.
- R 2 is the side chain of leucine, isoleucine, tert-leucine, phenylalanine, or tryptophan.
- the compound of Formula I is t-butylGly-boroPro.
- the stereochemical configuration at the carbon bearing X is L.
- the stereochemical configuration at the carbon bearing X is D.
- the stereochemical configuration at the carbon bearing R 2 is L.
- the stereochemical configuration at the carbon bearing R 2 is D.
- the stereochemical configuration at the carbon bearing X is L; and the stereochemical configuration at the carbon bearing R 2 is L.
- the stereochemical configuration at the carbon bearing X is L; and the stereochemical configuration at the carbon bearing R 2 is D.
- the stereochemical configuration at the carbon bearing X is D; and the stereochemical configuration at the carbon bearing R 2 is L.
- the stereochemical configuration at the carbon bearing X is D; and the stereochemical configuration at the carbon bearing R 2 is D.
- DASH serine protease means dipeptidyl peptidase (DPP) IV activity and/or structural homologues thereof. These proteins are enzymes that are united by their common post-proline-cleaving serine dipeptidase mechanism.
- DPP-VII originally named quiescent cell proline dipeptidase (QPP)
- QPP quiescent cell proline dipeptidase
- Val-boroPro also known as PT-100 or talabostat, appears to stimulate immunity via the activation of caspase-1 and induction of IL-1 ⁇ in macrophages, which in turn upregulates cytokine and chemokine expression in macrophages and stromal fibroblasts.
- Intracellular DPP 8 and/or 9 activity appears to be the relevant target for PT-100 in macrophages. This mechanism of action indicates a hitherto unforeseen regulatory role for intracellular DPPs in the immune system.
- ARI-4175 tertiary-butyl (abbreviated t-butyl) Gly-boroPro, is a dipeptide boronic acid that potently inhibits all six members of the prolyl peptidase family of serine proteases as an adjuvant for dendritic cell vaccines for the treatment of cancer. Similarly to PT-100, ARI-4175 inhibits DPP8/9 activity.
- dipeptide boronic acids preferably with a bulky, hydrophobic side chain
- isoleucine-boroPro butylglycine-boroPro
- phenylalanine-boroPro Phe-boroPro
- Cyg-boroPro cyclohexylglycine-boroPro
- PT-100 activates tumor immunity in mice via cytokine/chemokine upregulation in tumors and draining lymph nodes.
- cytokines as cancer vaccine adjuvants is not new: e.g., GM-CSF for sipuleucel-T and GM-CSF or IL-2 and IFN- ⁇ for vaccines in development.
- the orally active DPP8/9 inhibitors, PT-100 and ARI-4175 have the advantage of stimulating tumor-associated macrophages and stromal cells to produce a combination of cytokines and chemokines that can cooperate to activate tumor-specific effector T cells.
- IL-1 ⁇ produced by tumor-associated macrophages plays a pivotal role in activating proinflammatory responses and in promoting development of T h 17 cells in the tumor microenvironment.
- PT-100 was advanced into human trials in cancer and granted fast-track designation by the FDA.
- NHS non-Hodgkin's lymphoma
- NSCLC non-small cell lung cancer
- PT-100 ultimately failed to meet its goals in pivotal Phase III trials in NSCLC. Two factors are likely to have contributed to this failure.
- preclinical studies indicated that for optimal antitumor activity of PT-100 in mice, an endogenous immune response to the tumor is required. It was unlikely that any such underlying tumor immunity remained in the late-stage NSCLC patients studied in Phase III.
- ARI-4175 or other compounds that inhibit a plurality of mammalian DASH serine proteases e.g., compounds of Formula I
- DCT dendritic cell therapy
- trastuzamab cetuximab
- ipilimumab vemurafenib
- sorafenib or other cancer immunotherapies
- ARI-4175 and compounds that inhibit a plurality of mammalian DASH serine proteases are the first “orally active tumor antigens” of their kind.
- KRAS mutations found in approximately 40% of malignant colorectal cancers.
- a recent clinical trial found that KRAS mutations were correlated with resistance to cetuximab, while all of the patients who responded to cetuximab lacked the KRAS mutation.
- cetuximab produces a clinical response
- re-activation of the immune response with ARI-4175 may, alone or in combination with cetuximab or other immunotherapies, improve clinical outcomes in patients whose immune response is insufficient to kill the tumor or who have a refractory cancer.
- ARI-4175 or other compounds that inhibit a plurality of mammalian DASH serine proteases may also be used in combination with T cell adoptive transfer therapies.
- This treatment method uses T-cell-based cytotoxic responses to attack cancer cells.
- the adjuvant properties of ARI-4175 would allow it to be used as a pre-treatment before administration of tumor-infiltrating lymphocytes, or TIL, or as a post-treatment after administration of adoptive cell transfer.
- ARI-4175 or other compounds that inhibit a plurality of mammalian DASH serine proteases (e.g., compounds of Formula I) allows it to be used as an adjuvant in cancer patients whose cancer is currently in remission. Such patients would benefit from an increased anti-tumor immune response to avoid relapse.
- ARI-4175 and other compounds that inhibit a plurality of mammalian DASH serine proteases would perform synergistically with CTLA4 inhibitors, such as ipilimumab (Yervoy®), which is a receptor antagonist that increases immune activity.
- CTLA4 cytotoxic T lymphocyte antigen 4
- CD152 cytotoxic T lymphocyte antigen 4
- ARI-4175 or other compounds that inhibit a plurality of mammalian DASH serine proteases (e.g., compounds of Formula I) in combination with CD28 receptor agonists would work in a similar way to increase the activity of T cells.
- L-boroPro-pn 2 was coupled to an N-Boc protected unnatural amino acid Boc-Tle-OH 3 (CAS NO 62965-35-9) using HATU to render a protected dipeptide boronate Boc-Tle-boroPro-pn.
- PT-100 was synthesized as previously described in sufficient quantities for the studies described in the following examples.
- ARI-4175 is a nanomolar inhibitor of the DPP-IV-like serine proteases, including DPPs 8 and 9 (Table 1), which are the putative targets in PT-100's immune mechanism of action. Inhibition of DPP-IV and FAP activity may also contribute to the antitumor effect of PT-100 because selective abrogation of DPP-IV or FAP activity appears to slow tumor growth.
- mice bearing established RMS were vaccinated intramuscularly in a hind limb with RMS DC vaccine on day 10 after tumor inoculation.
- ARI-4175, PT-100 or vehicle was administered by daily gavage from day 10 onwards for 3 cycles of 5 days each as described herein: ARI-4175, 10 mg/kg, cycle 1 and 5 mg/kg cycles 2 and 3; PT-100, 1 mg/kg cycles 1 to 3.
- Another group of mice received vaccine but no compounds and groups of unvaccinated mice received compounds or vehicle. 8 replicate mice were treated in each regimen.
- the 1 mg/kg dose of PT-100 was previously shown to be optimal for activation of tumor immunity in C57BL/6 mice, and the dose cannot be increased much higher because the MTD for PT-100 is ⁇ 2 mg/kg in C57BL/6 mice. Therefore, the significant vaccine adjuvant effect of a 10/5-mg/kg dose of ARI-4175 suggests that ARI-4175 is less toxic than PT-100, and that it is possible to increase the dose of ARI-4175 to achieve greater tumor regression and mouse survival than is possible with PT-100 at tolerated doses in the RMS mouse model.
- FIG. 17A shows the experimental setup for priming of T cell donors and T cell recipients.
- FIG. 17B shows the tumor volume curve (mean ⁇ standard deviation) and survival curve.
- FIGS. 19A & 19B show a potent adjuvant to DC vaccination as evidenced by significantly improved survival and reduced RMS M3-9-M volume.
- FIG. 19A shows a late treatment model for DC vaccination and ARI-4175 treatment.
- the RMS cell line was derived from Ink4a/Arf ⁇ / ⁇ mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF) that develop malignant RMS with high penetrance.
- DC vaccine will be prepared by incubating bone marrow derived DCs with apoptotic bodies generated from RMS cells as previously described. Tumor growth was monitored by caliper measurement every 2 days.
- mice Female BALB/c mice were treated with various doses of PT-100 or ARI-4175 by oral gavage (PO) or intraperitoneal (IP) injection and serum was analyzed for chemokines ( FIGS. 4, 5, and 6 ). Blood was collected by cardiac puncture at various times post-dose and serum was prepared for analysis by ELISA. The samples were assayed for mouse mouse cytokines G-CSF and mouse CXCL1 using ELISA kits from R&D Systems (Cat. No. MCS00 and MKC00B respectively). All measurements were made in duplicate. Serum samples were diluted as necessary to obtain values within the range of the assays.
- FIG. 4 demonstrates that Val-boroPro (2054), but not Ala-boroPro (2243), stimulates G-CSF and CXCL1/KC in BALB/c mice.
- G-CSF and CXL1/KC are markers of anti-cancer immune enhancing activity.
- ARI-4175 (4175-2 in FIGS. 5 and 6 ) is a very potent inducer of cytokines. Stimulation of G-CSF increased until 6 h after administration; CXCL1 was rapidly induced at 3 h after administration but had disappeared by 6 h ( FIG. 5 ). ARI-4175 (4175-2) is at least 5 times more potent than PT-100 (2054) at inducing G-CSF and CXCL1 cytokines ( FIG. 6 ). Serum from ARI-4175 treated mice also had increased IL-18, IL-1 ⁇ and IFN- ⁇ compared to vehicle but at much lower levels than G-CSF and CXCL1.
- PT-100 stimulates expression of proinflammatory cytokine and chemokine mRNA 2 hours after oral administration to tumor-bearing mice.
- the PT-100 response is characterized by upregulation of IL-13, G-CSF, IL-6, CXCL1, CXCL9 and CXCL10 in tumor and lymph node tissue.
- ARI-4175 was recently found to stimulate development of IL-17 producing T h 17 cells in vitro (V. Kuchroo, unpublished data).
- T h -17 cells appear to contribute to effective antitumor immunity in certain cancers; therefore, IL-17 will be included with the cytokine/chemokine panel characterizing the response to PT-100 that we will investigate after administration of ARI-4175 and PT-100 to RMS-DC vaccinated mice.
- RNA expression will be assayed in RMS tumor and draining lymph node tissues 2 hours after compound administration at optimal doses.
- cDNA will be synthesized with an iScript kit (Biorad, Hercules, Calif.) from total RNA extracted by Trizol (Invitrogen, Carlsbad, Calif.), diluted 1:10 in water, and amplified for 40 cycles in a thermal cycler (cDNA denaturing, 95° C./15 s; annealing and extension, 60° C./30 s) using 10- ⁇ M unlabeled primer pairs in a 2 ⁇ iQ Sybergreen Supermix (Biorad). Reactions will use Taqman probes 5′-labeled with HEX, FAM or Texas Red and 3′-labeled with black hole quenchers (Biosearch Technologies, Novato, Calif.).
- Cytokine/chemokine target mRNA and 18s RNA reference control forward/reverse primer pairs and Taqman probes will be designed using Beacon Designer software (Premier Biosoft International, Palo Alto, Calif.). mRNA copy numbers will be calculated from cycle threshold values using standard curves with size-characterized reference cDNA, which will be synthesized and amplified from mouse tissue RNA, purified by electrophoresis and a gel purification kit (Qiagen, Valencia, Calif.), and quantified by PicoGreen (Invitrogen, Carlsbad, Calif.).
- ARI-4175 As shown in FIGS. 11 and 12 , treatment of mice with ARI-4175 also increased NK cell expression of the Fc ⁇ RIII receptor, CD16 and the degranulation marker LAMP-1. In vitro treatment of human NK cells also increased the activation marker, CD69 ( FIG. 15 ). The therapeutic effect of ARI-4175 might partially be due to the augmentation of ADCC through elevating expression of CD16 (Fc ⁇ RIIIA) and activating NK cells (based on CD69 upregulation).
- An effective vaccine for cancer would have the advantage of establishing immunological memory that can protect against disseminated metastasis or tumor regrowth following clinical response to initial treatment.
- Mice in which intramuscular RMS tumors are rejected after RMS DC vaccination followed by ARI-4175 or PT-100 treatment in Example 1 were rechallenged by intramuscular injection of 10 ⁇ 10 6 RMS cells at least 20-30 days after rejection of primary tumors. Mice were monitored for secondary tumor growth for a further 20-30 days without any additional therapeutic treatment.
- mice will also be challenged with the C57BL/6 tumor cell line, EL4 (ATCC, TIB-39). Groups of 4 mice were tested for immunological memory. Similar experiments demonstrating tumor-specific memory following PT-100 treatment have been described.
- CTL will be assayed ex vivo by the 51 Cr-release assay in tumor-draining lymph nodes and spleens of RMS tumor-bearing mice receiving the RMS DC vaccine and ARI-4175 or PT-100 treatments described in Example 1.
- the assay will be performed as previously described for the measurement of tumor-specific CTL responses stimulated by PT-100 in EL4 tumor-inoculated C57BL/6 mice. Specificity of CTLs will be investigated by comparing cytotoxicity against RMS versus EL4 cells.
- MTD maximum tolerated dose
- the MTD observed for SQ was 0.025 mg/kg for PT-100 and 0.01 mg/kg for ARI-4175.
- the MTD was 0.05 mg/kg for PT-100 and 0.1 mg/kg for ARI-4175.
- Evaluation of the plasma drug concentrations suggests toxicity results at equivalent plasma drug concentrations regardless of the route of administration. Toxicity is observed for the dose of drug that results in plasma drug concentration of 100+/ ⁇ 50 nM. This data is summarized in FIG. 20 .
- C57BL/6 mice were treated by oral gavage at various doses up to 40 mg/kg of ARI-4175 and up to 10 mg/kg of PT-100 (ARI-2054) daily for 5 days.
- PT-100 ARI-2054
- blood was drawn pre-dose and at 30 minutes post-dose and plasma drug concentrations were measured by LCMS.
- Oral availability of PT-100 is 3-4 times greater than that of ARI-4175 as evidenced by the plasma concentrations at the 10 mg/kg dose. Plasma concentrations are approximately proportional to dose over the range tested. Survival was 100% in this experiment but all groups showed significant weight loss over the 5 day treatment period. The results are shown in FIG. 21 .
- Pharmacokinetics of ARI-4175 was measured in normal BALB/c mice in both the open (linear) and closed (cyclic) forms of the drug by oral gavage (PO) and by, intraperitoneal (IP), subcutaneous (SQ) and intravenous (IV) injection.
- the open form of the drug was prepared by incubation of the drug at room temperature overnight at pH 2.
- the closed form was prepared by incubation overnight at pH 7.4 (in PBS).
- the open (linear) samples were neutralized by dilution into PBS immediately before administration.
- the treatment groups are listed below (Table 2).
- mice Groups of 3 mice will be inoculated intramuscularly with RMS cells and administered PT-100 and ARI-4175 by gavage at doses increasing from the MED determined in Example 1 up to the MTD determined in Example 6.
- One 5-day cycle of each compound will be given from day 10 to day 14 after tumor inoculation, and on day 18, specimens of tumor, draining lymph node, spleen, liver, lung and kidney tissue will be fixed in formalin and embedded in paraffin.
- H&E stained tissue sections from test mice will be compared histologically with sections from control mice.
- PT-100 has been shown to stimulate leukocytic infiltration of solid tumors. The tumor infiltrates are characterized by neutrophils concentrated at the borders of tumor and stromal tissue.
- Cytokine/chemokine responses to PT-100 are abrogated in IL-1R1 deficient B6.
- 129S7-Il1r1 tm1Imx /J mice Jackson Laboratory
- MTD should be significantly increased in IL-R1 mutant mice relative to congenic C57BL/6 mice. Therefore, the dose responses of serum G-CSF and CXCL1 cytokines will be compared by ELISA (R&D Systems) and the MTDs of ARI-4175 and PT-100 in B6.129S7-Il1r1 tm1Imx /J versus C57BL/6 control mice.
- MTDs will be determined in groups of 3 mice treated at increasing dose levels. G-CSF and CXCL-1 levels will be determined in serum sampled at 3 and 8 hours after compound administration. If IL-1R1 deficient mice are resistance to toxicity, and if histopathology in Experiment 6 reveals leukocytic infiltration of non-tumor tissue, IL-1R1 deficient and sufficient mice will be compared histologically to determine if toxicity is related to inflammatory disruption of organ function.
- Cetuximab (CTX) is an effective therapeutic agent in a number of malignancies. Current data indicate that about 40% of colorectal cancer patients bearing mutated K-ras do not benefit from this agent. A possible mechanism of the antitumor effect of cetuximab is mediated through antibody-dependent cell-mediated cytotoxicity (ADCC). This study investigated the potential of activity of ARI-4175, in the treatment of K-ras mutant colorectal cancer xenografts as a single agent or in combination with cetuximab.
- ADCC antibody-dependent cell-mediated cytotoxicity
- ARI-4175 alone or in combination with cetuximab was evaluated both in vitro and in vivo.
- the proliferation of K-ras mutant colon cancer cell lines DLD-1 and HCT-116 was detected after three days of culture in the medium containing various concentrations of ARI-4175 or cetuximab ( FIG. 10 ).
- ARI-4175 (10 nM-200 ⁇ M) alone or in combination with cetuximab did not show significant cytotoxicity on either DLD-1 or HCT-116 in cell culture ( FIG. 10 ).
- nude mice bearing DLD-1 or HCT-116 xenograft tumors were randomly divided into four groups, control, ARI-4175 alone, cetuximab alone and ARI-4175 plus cetuximab.
- ARI-4175 was administered orally at 100 g, q.d or b.i.d and cetuximab was injected intraperitoneally at 200 ⁇ g per week. Tumor measurements were conducted twice a week. In mice growth of both DLD-1 and HCT-116 tumors were significantly blocked by the application of ARI-4175 in a dose-dependent manner ( FIGS. 13A and 13B ).
- mice Female C57BL/6 mice were challenged subcutaneously with 1 ⁇ 10 6 MB49. Mice were orally gavaged on days 3-7 and 10-14. Tumor volume was monitored by caliper measurements. At a 20 ⁇ g dose, both PT-100 and ARI-4175 induce anti-tumor activity. ARI-4175 dosing at 200 ⁇ g induced full regression in 5 of 5 mice whereas PT-100 was toxic at the same dose.
Abstract
Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of T-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases. For example, the compound that inhibits a plurality of mammalian DASH serine proteases may be t-butylGly-boroPro.
Description
- This application is a continuation of U.S. patent application Ser. No. 14/948,777, filed Nov. 23, 2015; which is a continuation of U.S. patent application Ser. No. 14/353,408 filed Apr. 22, 2014, now U.S. Pat. No. 9,284,337; which is the U.S. national phase of International Patent Application No. PCT/US2012/065236, filed Nov. 15, 2012; which claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 61/562,497, filed Nov. 22, 2011.
- Cancer is America's second leading cause of death. Approved anticancer agents, both chemotherapeutic and targeted agents, are limited by toxicity and are ultimately ineffective against solid tumors, e.g.: lung, colorectal, breast, pancreatic, and prostate cancers, which account for more than 85% of cancer deaths. To kill tumors using the body's immune system, the failure of which has allowed the cancer to emerge, has long been the goal of cancer research. Val-boroPro, also known as PT-100 or talabostat, is a dipeptide boronic acid that showed remarkable efficacy in shrinking tumors in mice through immune activation. However, in Fast Track Phase III clinical trials, it did not meet its objectives, due to dose-limiting toxicity.
- The US Food and Drug Administration approved the first cancer vaccine, Provenge for prostate cancer, on Apr. 29, 2010. Provenge is a dendritic cell therapy (DCT); one of several exciting new immunotherapies sometimes called “cancer vaccines”. By supercharging the immune system, such vaccines can, in principle, find and remove the very last cancer cell, no matter where it hides, thus precluding mere remission after a course of treatment. Although the concept is now proven, cancer vaccines, including DCTs other than Provenge, have failed to achieve the desired efficacy in clinical trials, indicating the need to add immune stimulators, or adjuvants. However, less toxic adjuvants are needed to develop this approach clinically.
- One aspect of the present invention relates to a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the invention relates to a method of increasing antitumor immunity in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the invention relates to a method of stimulating or enhancing an immune response in a mammal, comprising administering to a mammal in need of an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Yet another aspect of the invention relates to a method of treating a condition characterized by abnormal cell proliferation, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the invention relates to a method of increasing cytokine and chemokine production in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the invention relates to a method of stimulating or enhancing production of T-cells in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases, wherein said T cells recognize an antigen on a malignant cell.
- In certain embodiments, the invention relates to any one of the methods described above, wherein the compound is represented by Formula I:
- wherein:
- X is B(Y1)(Y2) or CN;
- Y1 and Y2 are independently OH, or together with the boron atom to which they are attached represent a group that is hydrolysable to a boronic acid, or together with the boron atom to which they are attached form a 5- to 8-membered ring that is hydrolysable to a boronic acid;
- R1 is selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkynyl, carbonyl, carboxyl, ester, formate, ketone, thiocarbonyl, thioester, thioacetate, thioformate, amino, acylamino, amido, nitro, sulfate, sulfonate, sulfonamido, —(CH2)m—R7, —(CH2)m—OH, —(CH2)m—O-lower alkyl, —(CH2)m—O-lower alkenyl, —(CH2)n—O—(CH2)m—R7, —(CH2)m—SH, —(CH2)m—S-lower alkyl, —(CH2)m—S-lower alkenyl, or —(CH2)n—S—(CH2)m—R7, azido, cyano, isocyanato, thiocyanato, isothiocyanato, cyanato,
- R7 represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle;
- R8 independently represents hydrogen, —CH3, or —(CH2)n—CH3;
- m is 0, 1, 2, 3, 4, 5, or 6;
- R2 is a hydrophobic group selected from the group consisting of n-propyl, C4-C8 alkyl, C2-C8alkenyl, C2-C8alkynyl, C3-C8cycloalkyl, C2-C7heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and side chains of naturally occurring hydrophobic amino acids;
- n is 0, 1, or 2; and
- q is 0, 1, 2, 3, or 4.
- In certain embodiments, the invention relates to any one of the methods described above, wherein the compound is t-butylGly-boroPro.
-
FIG. 1 shows that Ala-boroPro (A-bP) and Val-boroPro (V-bP) both inhibit prolyl oligoproteases, but Ala-boroPro does not stimulate the immune system. Val-boroPro is a potent immune stimulator. -
FIG. 2 shows that PT-100 produces complete regression of early stage tumors but not of established tumors. -
FIG. 3 shows that PT-100+Dendritic Cell (DC) vaccine produces regression of established tumors. -
FIG. 4 shows that Val-boroPro (2054 in the figure), but not Ala-boroPro (2054 in the figure), stimulates G-CSF and CXCL1/KC in BALB/c mice. G-CSF and CXL1/KC are markers of anti-cancer immune enhancing activity. The experimental setup and results are discussed in Example 3. -
FIG. 5 shows that Ari-4175 (4175-2 in the figure) is a very potent inducer of cytokines in vivo. The experimental setup and results are discussed in Example 3. -
FIG. 6 shows that ARI-4175 (4175-2) is much more potent than PT-100 (2054) at inducing G-CSF and CXCL1 cytokines, which are markers of anti-cancer immune-enhancing activity. The experimental setup and results are discussed in Example 3. -
FIG. 7 shows that ARI-4175 establishes immunity to tumor rechallenge in the M3-9-M RMS model. The experimental setup and results are discussed in Example 4. -
FIG. 8A shows that ARI-4175 increases potency of a DC vaccine in a rhabdomyosarcoma (RMS) model to inhibit growth of established RMS. C57BL/6 mice were injected intramuscularly with RMS cells onday 0. Mice received a single subcutaneous vaccination onday 10 followed by daily gavage of 10 mg/kg (5 days) and 5 mg/kg (10 days) ARI-4175, 1 mg/kg PT-100 (15 days), or vehicle as described in Example 1. -
FIG. 8B shows that ARI-4175 increases mouse survival in a rhabdomyosarcoma (RMS) model. C57BL/6 mice were injected intramuscularly with RMS cells onday 0. Mice received a single subcutaneous vaccination onday 10 followed by daily gavage of 10 mg/kg (5 days) and 5 mg/kg (10 days) ARI-4175, 1 mg/kg PT-100 (15 days), or vehicle as described in Example 1. -
FIG. 9 shows tumor growth in individual mice in the experiment described inExperiment 1. -
FIG. 10 shows that ARI-4175 (4175) does not exhibit significant in vitro activity against colorectal cancer cell lines. There is also no activity when 4175 is combined with cetuximab (CTX). This is expected, since the antitumor effects of ARI-4175 and cetuximab are thought to be mediated through antibody-dependent cell-mediated cytotoxicity (ADCC). -
FIG. 11 shows that CD16 expression is upregulated on NK cells taken from nude mice treated with ARI-4175. -
FIG. 12 shows that LAMP-1 (CD107) expression is upregulated on NK cells taken from nude mice treated with ARI-4175. -
FIG. 13A shows the in vivo inhibition by ARI-4175 of colon cancer xenografts. The figure shows the inhibition of DLD1 xenografts by ARI-4175 alone or in combination with cetuximab (CTX). -
FIG. 13B shows the in vivo inhibition by ARI-4175 of colon cancer xenografts. The figure shows the inhibition of HCT-116 by ARI-4175 alone or in combination with cetuximab (CTX). -
FIG. 14 shows that cytotoxicity of splenocytes from C57BI/6 non-tumor-bearing mice treated with ARI-4175 and/or cetuximab (CTX) is enhanced against HCT116 tumor cells. -
FIG. 15 shows that ARI-4175 induces CD69 on human NK cells. The results shown are with cultured human PBLs from two healthy donors after a 1 day incubation. -
FIG. 16 shows that ARI-4175 is as effective as PT-100 but less toxic at a high dose. -
FIG. 17A shows that as adjuvant to tumor-primed T cell transfer, ARI-4175 induces tumor regression in late treatment RMS M3-9-M model. -
FIG. 17B shows that as adjuvant to tumor-primed T cell transfer, ARI-4175 induces tumor regression in late treatment RMS M3-9-M model. -
FIG. 18A shows that combination treatment with ARI-4175 and adoptive T cell transfer in Rag1−/− recipients significantly reduces RMS M3-9-M volume: Female Rag1−/− mice received naïve or RMS-primed T cells one day after tumor challenge. -
FIG. 18B shows that combination treatment with ARI-4175 and adoptive T cell transfer in Rag1−/− recipients significantly reduces RMS M3-9-M volume: byday 10, ARI-4175 treated mice had significantly smaller tumors than saline treated mice (naïve: n=5, p=0.0159; primed: n=5, p=0.0079). - Rag1−/− mice treated with tumor-primed T cells in combination with ARI-4175 had the smallest tumors overall.
-
FIG. 19A shows that ARI-4175 is a potent adjuvant to DC vaccination as evidenced by significantly improved survival and reduced RMS M3-9-M volume. The figure shows a late treatment model for DC vaccination and ARI-4175 treatment. -
FIG. 19B shows that ARI-4175 is a potent adjuvant to DC vaccination as evidenced by significantly improved survival and reduced RMS M3-9-M volume. The figure shows the tumor volume curve (mean±S.D.) and survival curve. -
FIG. 20 shows the results of a maximum tolerated dose (MTD) study using SD rats with the data taken 30 minutes post-dose. -
FIG. 21 shows a dose-plasma response curve for PT-100 and ARI-4175. -
FIG. 22 shows pharmacokinetic data for the open vs. closed forms of ARI-4175. Under acidic conditions, ARI-4175 exists in an open, or linear, form; under neutral or basic conditions, a closed, cyclized form is highly favored. -
FIG. 23 shows tumor growth in individual mice in the RMS model. - One aspect of the present invention relates to a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- Another aspect of the present invention relates to a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases, wherein the compound is not Val-boroPro.
- Another aspect of the present invention relates to any one of the foregoing methods, wherein said compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- Another aspect of the present invention relates to any one of the foregoing methods, wherein the cancer is selected from the group consisting of basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, CNS cancer, colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, intra-epithelial neoplasm, kidney cancer, larynx cancer, leukemia, acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, melanoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, renal cancer, cancer of the respiratory system, sarcoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, and cancer of the urinary system.
- In other embodiments, the cancer is selected from the group consisting of prostate cancer, colorectal cancer, multiple myeloma, and non-small cell lung cancer.
- In certain other embodiments, the cancer is selected from lung cancer, colorectal cancer, breast cancer, pancreatic cancer and prostate cancer.
- In one embodiment, the cancer is lung cancer.
- In another embodiment, the cancer is non-small cell lung cancer.
- In yet another embodiment, the cancer is colorectal cancer.
- In certain embodiments, the cancer is breast cancer.
- In certain other embodiments, the cancer is pancreatic cancer.
- In another embodiment, the cancer is prostate cancer.
- In certain embodiments, the cancer is metastatic.
- Another aspect of the invention relates to any one of the methods described above, further comprising co-administering to the mammal a therapeutically effective amount of tumor-primed T-cells.
- In certain embodiments, the tumor-primed T-cells are administered prior to the administration of the compound.
- In certain embodiments, the tumor-primed T-cells are administered subsequent to the administration of the compound.
- In certain embodiments, the tumor-primed T-cells are administered concurrently with administration of the compound.
- Another aspect of the invention relates to any one of the methods described above, further comprising co-administering to the mammal a therapeutically effective amount of an orally active tumor antigen.
- Yet another aspect of the invention relates to any one of the methods described above, further comprising co-administering to the mammal a therapeutically effective amount of a dendritic cell vaccine.
- Still another aspect of the invention relates to any one of the methods described above, further comprising administration of an adjuvant.
- Another aspect of the present invention relates to any one of the aforementioned embodiments, further comprising treating the mammal with a second therapy selected from the group consisting of surgery, radiation and chemotherapy.
- In one embodiment, the second therapy is surgery.
- In another embodiment, the second therapy is radiation.
- In yet another embodiment, the second therapy is chemotherapy.
- In certain embodiments, the chemotherapy is selected from the group consisting of of ipilimumab, vemurafenib, GDC-0879, PLX-4720, aldesleukin, asparaginase, bleomycin sulfate, carboplatin, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin hydrochloride, docetaxel, doxorubicin, doxorubicin hydrochloride, epirubicin hydrochloride, etoposide, etoposide phosphate, floxuridine, fludarabine, fluorouracil, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, interferons, interferon-α2a, interferon-α2b, interferon-αn3, interferon-α1b, interleukins, irinotecan, mechlorethamine hydrochloride, melphalan, mercatopurine, methotrexate, methotrexate sodium, mitomycin, mitoxantrone, paclitaxel, pegaspargase, pentostatin, prednisone, profimer sodium, procabazine hydrochloride, taxol, taxotere, teniposide, topotecan hydrochloride, vinblastine sulfate, vincristine sulfate and vinorelbine tartrate.
- In certain embodiments the chemotherapy is selected from the group consisting of bleomycin sulfate, carboplatin, cisplatin, docetaxel, doxorubicin, doxorubicin hydrochloride, fluorouracil, gemcitabine, gemcitabine hydrochloride, methotrexate, methotrexate sodium, paclitaxel, taxol, taxotere, vinblastine sulfate and vincristine sulfate.
- In certain embodiments, the chemotherapy is a dipeptidylpeptidase IV inhibitor.
- In certain other embodiments, the chemotherapy is a FAP-activated chemotherapeutic, a FAP-activated dipeptidylpeptidase IV inhibitor, or a FAP-activated proteasome inhibitor.
- In still other embodiments, the chemotherapy is a FAP-activated proteasome inhibitor.
- In certain embodiments, the chemotherapy is an antibody.
- In certain other embodiments, the antibody is selected from the group consisting of trastuzamab, cetuximab, bevacizumab, and rituximab.
- One aspect of the present invention relates to a method of increasing antitumor immunity in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- In certain embodiments, the compound is not Val-boroPro.
- In certain other embodiments, the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- In yet other embodiments, the antitumor immunity is increased for tumors selected from the group consisting of lung tumors, lymphomas, breast tumors, colorectal tumors, thyroid tumors, uterine tumors, pancreatic tumors, prostate tumors, skin tumors, kidney tumors, liver tumors and brain tumors.
- In other embodiments, the antitumor immunity is increased for tumors selected from the group consisting of lung tumors, breast tumors, colorectal tumors, pancreatic tumors and prostate tumors.
- In certain other embodiments, the antitumor immunity comprises antibody-dependent cell-mediated cytotoxicity.
- Another aspect of the invention relates to a method of stimulating or enhancing an immune response in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- In certain embodiments, the compound is not Val-boroPro.
- In certain other embodiments, the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- In still other embodiments, the immune response is stimulated.
- In still yet further embodiments, the immune response is enhanced.
- In certain embodiments, the immune response comprises antibody-dependent cell-mediated cytotoxicity.
- In certain other embodiments, the mammal has cancer or is at risk of developing cancer.
- In still other embodiments, the mammal is in remission of cancer.
- In still yet further embodiments, the mammal has a refractory or resistant cancer.
- Another aspect of the invention relates to a method of treating a condition characterized by abnormal cell proliferation, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- In certain embodiments, the compound is not Val-boroPro.
- In certain embodiments, the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- In certain embodiments, the abnormal cell proliferation is cancer, a blood vessel proliferative disorder or a fibrotic disorder.
- In certain embodiments, the abnormal cell proliferation is abnormal angiogenesis.
- Another aspect of the invention relates to a method of increasing cytokine and/or chemokine production in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
- In certain embodiments, the compound is not Val-boroPro.
- In certain other embodiments, the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- Another aspect of the invention relates to a method of stimulating or enhancing production of T-cells in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases, wherein said T-cells recognize an antigen on a malignant cell.
- In certain embodiments, the compound is not Val-boroPro.
- In certain other embodiments, the compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
- In certain other embodiments, the production of T-cells is stimulated.
- In yet other embodiments, the production of T-cells is enhanced.
- In still yet other embodiments, the malignant cell is a carcinoma, sarcoma, leukemia, lymphoma or myeloma.
- In certain embodiments, the mammal is a primate, canine, equine, feline or bovine.
- In certain other embodiments, the mammal is a human.
- In certain embodiments, the compound is administered orally or parenterally.
- In certain other embodiments, the compound is administered parenterally.
- In yet other embodiments, the compound is administered orally.
- In certain embodiments, the compound is administered in a solid dosage form.
- In certain other embodiments, the solid dosage form is a tablet, capsule or pill.
- In yet other embodiments, the solid dosage form is a tablet.
- In certain embodiments, the compound is administered in an amount sufficient to stimulate the immune system without dose limiting toxicity.
- In certain embodiments, the invention relates to any one of the methods described above, wherein the compound is represented by Formula I:
- wherein:
- X is B(Y1)(Y2) or CN;
- Y1 and Y2 are independently OH, or together with the boron atom to which they are attached represent a group that is hydrolysable to a boronic acid, or together with the boron atom to which they are attached form a 5- to 8-membered ring that is hydrolysable to a boronic acid;
- R1 is selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkynyl, carbonyl, carboxyl, ester, formate, ketone, thiocarbonyl, thioester, thioacetate, thioformate, amino, acylamino, amido, nitro, sulfate, sulfonate, sulfonamido, —(CH2)m—R7, —(CH2)m—OH, —(CH2)m—O-lower alkyl, —(CH2)m—O-lower alkenyl, —(CH2)n—O—(CH2)m—R7, —(CH2)m—SH, —(CH2)m—S-lower alkyl, —(CH2)m—S-lower alkenyl, or —(CH2)n—S—(CH2)m—R7, azido, cyano, isocyanato, thiocyanato, isothiocyanato, cyanato,
- R7 represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle;
- R8 independently represents hydrogen, —CH3, or —(CH2)n—CH3;
- m is 0, 1, 2, 3, 4, 5, or 6;
- R2 is a hydrophobic group selected from the group consisting of n-propyl, C4-C8 alkyl, C2-C8alkenyl, C2-C8alkynyl, C3-C8cycloalkyl, C2-C7heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and side chains of naturally occurring hydrophobic amino acids;
- n is 0, 1, or 2; and
- q is 0, 1, 2, 3, or 4.
- In certain embodiments, q is 0, 1, or 2.
- In certain other embodiments, q is 0.
- In yet other embodiments, n is 0.
- In still yet other embodiments, n is 1.
- In certain other embodiments, n is 2.
- In certain embodiments, X is B(Y1)(Y2).
- In certain other embodiments, X is B(OH)2.
- In certain embodiments, n is 1; q is 0; and X is B(OH)2.
- In certain embodiments, R2 is selected from the group consisting of t-butyl, isobutyl, pentyl, cyclohexyl, benzyl, or naphthyl.
- In certain other embodiments, R2 is selected from the group consisting of t-butyl, isobutyl, or pentyl.
- In still yet other embodiments, R2 is t-butyl.
- In certain embodiments, R2 is the side chain of a naturally occurring hydrophobic amino acid.
- In certain other embodiments, R2 is the side chain of leucine, isoleucine, tert-leucine, phenylalanine, or tryptophan.
- In certain embodiments, the compound of Formula I is t-butylGly-boroPro.
- In certain embodiments, the stereochemical configuration at the carbon bearing X is L.
- In certain other embodiments, the stereochemical configuration at the carbon bearing X is D.
- In certain embodiments, the stereochemical configuration at the carbon bearing R2 is L.
- In certain other embodiments, the stereochemical configuration at the carbon bearing R2 is D.
- In certain embodiments, the stereochemical configuration at the carbon bearing X is L; and the stereochemical configuration at the carbon bearing R2 is L.
- In certain other embodiments, the stereochemical configuration at the carbon bearing X is L; and the stereochemical configuration at the carbon bearing R2 is D.
- In yet other embodiments, the stereochemical configuration at the carbon bearing X is D; and the stereochemical configuration at the carbon bearing R2 is L.
- In certain embodiments, the stereochemical configuration at the carbon bearing X is D; and the stereochemical configuration at the carbon bearing R2 is D.
- The term “DASH serine protease” means dipeptidyl peptidase (DPP) IV activity and/or structural homologues thereof. These proteins are enzymes that are united by their common post-proline-cleaving serine dipeptidase mechanism. For example, DPP-VII, originally named quiescent cell proline dipeptidase (QPP), is a DASH serine protease.
- Val-boroPro, also known as PT-100 or talabostat, appears to stimulate immunity via the activation of caspase-1 and induction of IL-1β in macrophages, which in turn upregulates cytokine and chemokine expression in macrophages and stromal fibroblasts.
Intracellular DPP 8 and/or 9 activity appears to be the relevant target for PT-100 in macrophages. This mechanism of action indicates a hitherto unforeseen regulatory role for intracellular DPPs in the immune system. - ARI-4175, tertiary-butyl (abbreviated t-butyl) Gly-boroPro, is a dipeptide boronic acid that potently inhibits all six members of the prolyl peptidase family of serine proteases as an adjuvant for dendritic cell vaccines for the treatment of cancer. Similarly to PT-100, ARI-4175 inhibits DPP8/9 activity. Other dipeptide boronic acids, preferably with a bulky, hydrophobic side chain such as isoleucine-boroPro, butylglycine-boroPro, phenylalanine-boroPro (Phe-boroPro), and cyclohexylglycine-boroPro (Cyg-boroPro) are expected to perform in a similar way. Routine experimentation by one skilled in the art could determine which compounds that inhibit a plurality of mammalian DASH serine proteases (e.g., compounds of Formula I) could be used successfully in the claimed methods.
- PT-100 activates tumor immunity in mice via cytokine/chemokine upregulation in tumors and draining lymph nodes. The use of cytokines as cancer vaccine adjuvants is not new: e.g., GM-CSF for sipuleucel-T and GM-CSF or IL-2 and IFN-γ for vaccines in development. However, in comparison to these applications, the orally active DPP8/9 inhibitors, PT-100 and ARI-4175, have the advantage of stimulating tumor-associated macrophages and stromal cells to produce a combination of cytokines and chemokines that can cooperate to activate tumor-specific effector T cells. Among the cytokines and chemokines upregulated by PT-100, IL-1β, CXCL9 and CXCL10 are particularly noteworthy. IL-1β produced by tumor-associated macrophages plays a pivotal role in activating proinflammatory responses and in promoting development of
T h17 cells in the tumor microenvironment. - Based on strong preclinical antitumor activity and a novel mechanism of action, PT-100 was advanced into human trials in cancer and granted fast-track designation by the FDA. However, despite some signals of clinical activity in non-randomized Phase II studies of non-Hodgkin's lymphoma (NHL), metastatic melanoma and non-small cell lung cancer (NSCLC), PT-100 ultimately failed to meet its goals in pivotal Phase III trials in NSCLC. Two factors are likely to have contributed to this failure. Most importantly, preclinical studies indicated that for optimal antitumor activity of PT-100 in mice, an endogenous immune response to the tumor is required. It was unlikely that any such underlying tumor immunity remained in the late-stage NSCLC patients studied in Phase III. Secondly, dose-limiting toxicity in cancer patients appeared to prevent administration of high enough PT-100 doses for consistent immune stimulation patient to patient. The studies by Fry et al. suggest that PT-100's mechanism of action should be most effective clinically when employed to boost cancer vaccines. It is possible that PT-100 might be clinically successful when used with an appropriate vaccine that can prime tumor-specific T cells; but it is the goal of the present invention to identify an analog with lower toxicity that will achieve clinical success in humans.
- ARI-4175 or other compounds that inhibit a plurality of mammalian DASH serine proteases (e.g., compounds of Formula I), alone or in combination with dendritic cell therapy (DCT), trastuzamab, cetuximab, ipilimumab, vemurafenib, sorafenib, or other cancer immunotherapies, have a significant advantage over other cancer immunotherapies because they are orally active small molecules. They elicit immune activation similar to difficult and expensive DCT or antibody treatments, but can be administered much more easily. ARI-4175 and compounds that inhibit a plurality of mammalian DASH serine proteases (e.g., compounds of Formula I) are the first “orally active tumor antigens” of their kind.
- Many patients do not respond to cetuximab, or develop resistance after initial response to therapy. This is due to the cancer developing resistance to the immune system of the patient. The immune response is still present, but is either no longer strong enough to kill the tumor or the tumor becomes invisible to the immune system. One example is the KRAS mutation found in approximately 40% of malignant colorectal cancers. A recent clinical trial (Lièvre et al., Cancer Res. 2006, 66 (8), 3992) found that KRAS mutations were correlated with resistance to cetuximab, while all of the patients who responded to cetuximab lacked the KRAS mutation. Although the molecular mechanisms by which cetuximab produces a clinical response remain unknown, re-activation of the immune response with ARI-4175 may, alone or in combination with cetuximab or other immunotherapies, improve clinical outcomes in patients whose immune response is insufficient to kill the tumor or who have a refractory cancer.
- ARI-4175 or other compounds that inhibit a plurality of mammalian DASH serine proteases (e.g., compounds of Formula I) may also be used in combination with T cell adoptive transfer therapies. This treatment method uses T-cell-based cytotoxic responses to attack cancer cells. The adjuvant properties of ARI-4175 would allow it to be used as a pre-treatment before administration of tumor-infiltrating lymphocytes, or TIL, or as a post-treatment after administration of adoptive cell transfer.
- The low toxicity of ARI-4175 (or other compounds that inhibit a plurality of mammalian DASH serine proteases (e.g., compounds of Formula I) allows it to be used as an adjuvant in cancer patients whose cancer is currently in remission. Such patients would benefit from an increased anti-tumor immune response to avoid relapse.
- It is expected that ARI-4175 and other compounds that inhibit a plurality of mammalian DASH serine proteases (e.g., compounds of Formula I) would perform synergistically with CTLA4 inhibitors, such as ipilimumab (Yervoy®), which is a receptor antagonist that increases immune activity. The CTLA4 (cytotoxic T lymphocyte antigen 4), also known as CD152, is a protein receptor that downregulates the immune system. ARI-4175 or other compounds that inhibit a plurality of mammalian DASH serine proteases (e.g., compounds of Formula I) in combination with CD28 receptor agonists would work in a similar way to increase the activity of T cells.
- The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
- Commercially available L-boroPro-
pn 2 was coupled to an N-Boc protected unnatural amino acid Boc-Tle-OH 3 (CAS NO 62965-35-9) using HATU to render a protected dipeptide boronate Boc-Tle-boroPro-pn. Concurrent removal of both protection groups by trichloroborane (BCl3) followed by reverse-phase HPLC purification yields the desired product 1 (ARI-4175) as an HCl salt. - PT-100 was synthesized as previously described in sufficient quantities for the studies described in the following examples.
- ARI-4175 is a nanomolar inhibitor of the DPP-IV-like serine proteases, including
DPPs 8 and 9 (Table 1), which are the putative targets in PT-100's immune mechanism of action. Inhibition of DPP-IV and FAP activity may also contribute to the antitumor effect of PT-100 because selective abrogation of DPP-IV or FAP activity appears to slow tumor growth. -
TABLE 1 Potency of inhibition of DPP-IV-like protease activities in vitro IC50 1 (nM) Inhibitor DPP-IV DPP8 DPP9 DPP-II FAP PREP2 PT-100 (Val-boroPro) 0.7 3.6 1.7 8.2 17.0 35.0 ARI-4175 1.6 5.1 1.9 88.0 32.0 24.0 (t-butylGly-boroPro) 150% mean inhibitory concentration 2Prolyl endopeptidase - C57BL/6 mice bearing established RMS were vaccinated intramuscularly in a hind limb with RMS DC vaccine on
day 10 after tumor inoculation. ARI-4175, PT-100 or vehicle was administered by daily gavage fromday 10 onwards for 3 cycles of 5 days each as described herein: ARI-4175, 10 mg/kg,cycle kg cycles kg cycles 1 to 3. Another group of mice received vaccine but no compounds and groups of unvaccinated mice received compounds or vehicle. 8 replicate mice were treated in each regimen. - As shown in
FIG. 8A , administration of ARI-4175 by itself significantly slowed tumor growth (FIG. 8A ) and produced tumor regression in 3/8 mice by day 25 (FIG. 9 ). In combination with vaccine, ARI-4175 produced regression in 6/8 mice (FIG. 9 ) and increased mouse survival significantly (P=0.0045;FIG. 1B ). In contrast, PT-100 administered at a dose of 1 mg/kg, either with or without DC vaccination, failed to produce tumor regression (FIG. 2 ) byday 25 or significant inhibition of tumor growth (FIG. 8A ), and tumor growth was only reduced in 2 out of 6 mice treated with PT-100 and the vaccine (FIG. 9 ). The 1 mg/kg dose of PT-100 was previously shown to be optimal for activation of tumor immunity in C57BL/6 mice, and the dose cannot be increased much higher because the MTD for PT-100 is ˜2 mg/kg in C57BL/6 mice. Therefore, the significant vaccine adjuvant effect of a 10/5-mg/kg dose of ARI-4175 suggests that ARI-4175 is less toxic than PT-100, and that it is possible to increase the dose of ARI-4175 to achieve greater tumor regression and mouse survival than is possible with PT-100 at tolerated doses in the RMS mouse model. -
FIG. 17A shows the experimental setup for priming of T cell donors and T cell recipients.FIG. 17B shows the tumor volume curve (mean±standard deviation) and survival curve. Mice receiving ARI-4175 alone had significantly smaller tumors compared to saline (n=10, p=0.0019). Though ARI-4175+primed T cell recipients had smaller tumors, the difference was not significant when compared to ARI-4175+naïve T cell recipients (n=10, p=0.0755). Eight of ten ARI-4175+primed T cell recipients survived today 80, however this was not significant compared to the 40% survival of ARI-4175+naïve T cell recipients (n=10, p=0.0658). -
FIGS. 18A and B show that combination treatment with ARI-4175 and adoptive T cell transfer in Rag1−/− recipients significantly reduces RMS M3-9-M volume. (A) Female Rag1−/− mice received naïve or RMS-primed T cells one day after tumor challenge. (B) Byday 10, ARI-4175 treated mice had significantly smaller tumors than saline treated mice (naïve: n=5, p=0.0159; primed: n=5, p=0.0079). Rag1−/− mice treated with tumor-primed T cells in combination with ARI-4175 had the smallest tumors overall. - ARI-4175 is a potent adjuvant to DC vaccination as evidenced by significantly improved survival and reduced RMS M3-9-M volume (
FIGS. 19A & 19B ).FIG. 19A shows a late treatment model for DC vaccination and ARI-4175 treatment.FIG. 19B shows the tumor volume curve (mean±s.d.) and survival curve. Both groups treated with ARI-4175 had significantly improved survival compared to controls (sham vaccine: n=7, p<0.001, DC vaccine: n=7, p<0.001). Mice treated with a combination therapy using ARI-4175 and DC vaccine had significantly smaller tumors compared to mice treated with ARI-4175 alone (n=7, p=0.0481). - The RMS cell line was derived from Ink4a/Arf−/− mice transgenic for hepatocyte growth factor/scatter factor (HGF/SF) that develop malignant RMS with high penetrance. DC vaccine will be prepared by incubating bone marrow derived DCs with apoptotic bodies generated from RMS cells as previously described. Tumor growth was monitored by caliper measurement every 2 days.
- Method for Cytokine Assay in BALB/c Mice.
- Female BALB/c mice were treated with various doses of PT-100 or ARI-4175 by oral gavage (PO) or intraperitoneal (IP) injection and serum was analyzed for chemokines (
FIGS. 4, 5, and 6 ). Blood was collected by cardiac puncture at various times post-dose and serum was prepared for analysis by ELISA. The samples were assayed for mouse mouse cytokines G-CSF and mouse CXCL1 using ELISA kits from R&D Systems (Cat. No. MCS00 and MKC00B respectively). All measurements were made in duplicate. Serum samples were diluted as necessary to obtain values within the range of the assays. Optimal dilutions required varied depending on the test agent and can range from no dilution for control samples or test agents with no activity to 1:1000 dilution for very high samples. For agents that produce a positive response the strongest signal was observed at 2 hrs post-dose for CXCL1 and at 6 hours post-dose for G-CSF. The dose response varies with test agent but 20 μg/mouse dose is an acceptable baseline dose for response assessment. Typically 6 animals are measured for each agent at each time point. -
FIG. 4 demonstrates that Val-boroPro (2054), but not Ala-boroPro (2243), stimulates G-CSF and CXCL1/KC in BALB/c mice. G-CSF and CXL1/KC are markers of anti-cancer immune enhancing activity. - ARI-4175 (4175-2 in
FIGS. 5 and 6 ) is a very potent inducer of cytokines. Stimulation of G-CSF increased until 6 h after administration; CXCL1 was rapidly induced at 3 h after administration but had disappeared by 6 h (FIG. 5 ). ARI-4175 (4175-2) is at least 5 times more potent than PT-100 (2054) at inducing G-CSF and CXCL1 cytokines (FIG. 6 ). Serum from ARI-4175 treated mice also had increased IL-18, IL-1β and IFN-γ compared to vehicle but at much lower levels than G-CSF and CXCL1. - PT-100 stimulates expression of proinflammatory cytokine and
chemokine mRNA 2 hours after oral administration to tumor-bearing mice. The PT-100 response is characterized by upregulation of IL-13, G-CSF, IL-6, CXCL1, CXCL9 and CXCL10 in tumor and lymph node tissue. ARI-4175 was recently found to stimulate development of IL-17 producingT h17 cells in vitro (V. Kuchroo, unpublished data). Th-17 cells appear to contribute to effective antitumor immunity in certain cancers; therefore, IL-17 will be included with the cytokine/chemokine panel characterizing the response to PT-100 that we will investigate after administration of ARI-4175 and PT-100 to RMS-DC vaccinated mice. RNA expression will be assayed in RMS tumor and draininglymph node tissues 2 hours after compound administration at optimal doses. We will use the RT-PCR procedure used previously to analyze the upregulation of cytokines and chemokines by PT-100 in mice bearing A549 lung carcinoma xenografts. cDNA will be synthesized with an iScript kit (Biorad, Hercules, Calif.) from total RNA extracted by Trizol (Invitrogen, Carlsbad, Calif.), diluted 1:10 in water, and amplified for 40 cycles in a thermal cycler (cDNA denaturing, 95° C./15 s; annealing and extension, 60° C./30 s) using 10-μM unlabeled primer pairs in a 2× iQ Sybergreen Supermix (Biorad). Reactions will useTaqman probes 5′-labeled with HEX, FAM or Texas Red and 3′-labeled with black hole quenchers (Biosearch Technologies, Novato, Calif.). Cytokine/chemokine target mRNA and 18s RNA reference control forward/reverse primer pairs and Taqman probes will be designed using Beacon Designer software (Premier Biosoft International, Palo Alto, Calif.). mRNA copy numbers will be calculated from cycle threshold values using standard curves with size-characterized reference cDNA, which will be synthesized and amplified from mouse tissue RNA, purified by electrophoresis and a gel purification kit (Qiagen, Valencia, Calif.), and quantified by PicoGreen (Invitrogen, Carlsbad, Calif.). - As shown in
FIGS. 11 and 12 , treatment of mice with ARI-4175 also increased NK cell expression of the FcγRIII receptor, CD16 and the degranulation marker LAMP-1. In vitro treatment of human NK cells also increased the activation marker, CD69 (FIG. 15 ). The therapeutic effect of ARI-4175 might partially be due to the augmentation of ADCC through elevating expression of CD16 (FcγRIIIA) and activating NK cells (based on CD69 upregulation). - An effective vaccine for cancer would have the advantage of establishing immunological memory that can protect against disseminated metastasis or tumor regrowth following clinical response to initial treatment. Mice in which intramuscular RMS tumors are rejected after RMS DC vaccination followed by ARI-4175 or PT-100 treatment in Example 1 were rechallenged by intramuscular injection of 10×106 RMS cells at least 20-30 days after rejection of primary tumors. Mice were monitored for secondary tumor growth for a further 20-30 days without any additional therapeutic treatment. In order to demonstrate immunological specificity of protection, mice will also be challenged with the C57BL/6 tumor cell line, EL4 (ATCC, TIB-39). Groups of 4 mice were tested for immunological memory. Similar experiments demonstrating tumor-specific memory following PT-100 treatment have been described.
- As shown in
FIG. 7 , female C57BL/6 mice were challenged intramuscularly with 1×106 RMS M3-9-M onday 0. Mice were orally gavaged with 200 μg ARI-4175 on days 3-7, 17-21, 24-28, and 31-35. Tumor-free survivors were rechallenged on day 56 with 5×105 RMS M3-9-M and monitored with no additional 4175 treatment. Following rechallenge, RMS M3-9-M showed initial growth followed by rejection in all mice (n=7, p=0.0175). - CTL will be assayed ex vivo by the 51Cr-release assay in tumor-draining lymph nodes and spleens of RMS tumor-bearing mice receiving the RMS DC vaccine and ARI-4175 or PT-100 treatments described in Example 1. The assay will be performed as previously described for the measurement of tumor-specific CTL responses stimulated by PT-100 in EL4 tumor-inoculated C57BL/6 mice. Specificity of CTLs will be investigated by comparing cytotoxicity against RMS versus EL4 cells.
- Previously, in C57BL/6 mice administered PT-100 at doses above the MTD (˜2 mg/kg/day), no obvious signs of toxicity were observed prior to death; therefore, the end point for determination of MTD was mortality in this experiment. In order to gain insight into the causes of toxicity, histopathology was investigated to determine the dose response of plasma cytokine and chemokine levels. The cytokine/chemokine assay was used to determine whether toxicity is related to PT-100's putative mechanism of action. Preliminary experiments indicated that blockade of cytokine/chemokine responses with the IL-1R antagonist, anakinra, does not alter the toxicity of PT-100 in rats, suggesting that the toxicity of PT-100 may not be due to systemic cytokine/chemokine production.
- Summary of Rat Toxicity.
- A maximum tolerated dose (MTD) study was undertaken to compare the MTD for ARI-4175 (t-BuGly-boroPro) and PT-100 (Val-boroPro, ARI-2054) in Sprague Dawley rats. Animals were dosed by either subcutaneous injection (SQ) or oral gavage (PO). Six animals were used at each dose. A blood sample was drawn from the tail at 30 minutes post-dose which was used to measure plasma drug concentrations. The starting dose for both compounds was 0.05 mg/kg body weight and then the dose was adjusted up or down for each drug to determine the maximum dose at which there was 100% survival. At the starting dose of 0.05 mg/kg body weight SQ, both ARI-4175 and PT-100 treatment resulted in at least one animal death within the first 24 hours. A 0.01 mg/kg body weight dose, SQ, did not result in any deaths and no adverse effects were observed for 48 hours post-dose. A third experiment was done at a dose of 0.025 mg/kg body weight which resulted in one death in the ARI-4175 group but no deaths in the PT-100 group. The study was repeated with oral dosing starting again at 0.05 mg/kg body weight. Both drugs were apparently more tolerated by the oral dose as there were no adverse effects in this experiment at 0.05 mg/kg PO. Increasing the dose to 0.1 mg/kg PO resulted in 2 deaths in the PT-100 group but no adverse effects with ARI-4175. At 0.25 mg/kg ARI-4175 PO there was one death. Therefore the MTD observed for SQ was 0.025 mg/kg for PT-100 and 0.01 mg/kg for ARI-4175. By the oral route the MTD was 0.05 mg/kg for PT-100 and 0.1 mg/kg for ARI-4175. Evaluation of the plasma drug concentrations suggests toxicity results at equivalent plasma drug concentrations regardless of the route of administration. Toxicity is observed for the dose of drug that results in plasma drug concentration of 100+/−50 nM. This data is summarized in
FIG. 20 . - Mouse Toxicity Plasma vs. Dose Figures.
- C57BL/6 mice were treated by oral gavage at various doses up to 40 mg/kg of ARI-4175 and up to 10 mg/kg of PT-100 (ARI-2054) daily for 5 days. On the 5th day blood was drawn pre-dose and at 30 minutes post-dose and plasma drug concentrations were measured by LCMS. Oral availability of PT-100 is 3-4 times greater than that of ARI-4175 as evidenced by the plasma concentrations at the 10 mg/kg dose. Plasma concentrations are approximately proportional to dose over the range tested. Survival was 100% in this experiment but all groups showed significant weight loss over the 5 day treatment period. The results are shown in
FIG. 21 . - PK for 4175 in Mice.
- Pharmacokinetics of ARI-4175 was measured in normal BALB/c mice in both the open (linear) and closed (cyclic) forms of the drug by oral gavage (PO) and by, intraperitoneal (IP), subcutaneous (SQ) and intravenous (IV) injection. The open form of the drug was prepared by incubation of the drug at room temperature overnight at
pH 2. The closed form was prepared by incubation overnight at pH 7.4 (in PBS). The open (linear) samples were neutralized by dilution into PBS immediately before administration. The treatment groups are listed below (Table 2). -
TABLE 2 Group Dose Route n 1 1 mpk PO 4 2 1 mpk IP 4 3 1 mpk SQ 4 4 0.5 mpk IV 6 - Blood was collected from the tail vein for all groups except the IV groups. The IV injection was made in the tail vein and therefore blood was collected from a distant site (submandibular vein). Plasma samples were prepared and the concentration of ARI-4175 in each sample was measured by LC-MS. The results are shown in
FIG. 22 . - Groups of 3 mice will be inoculated intramuscularly with RMS cells and administered PT-100 and ARI-4175 by gavage at doses increasing from the MED determined in Example 1 up to the MTD determined in Example 6. One 5-day cycle of each compound will be given from
day 10 today 14 after tumor inoculation, and on day 18, specimens of tumor, draining lymph node, spleen, liver, lung and kidney tissue will be fixed in formalin and embedded in paraffin. H&E stained tissue sections from test mice will be compared histologically with sections from control mice. PT-100 has been shown to stimulate leukocytic infiltration of solid tumors. The tumor infiltrates are characterized by neutrophils concentrated at the borders of tumor and stromal tissue. Comparison of tumor sections from ARI-4175 treated mice versus sections from PT-100 treated mice will determine whether ARI-4175 also promotes tumor infiltration. It is possible that the toxicity of PT-100 results from leukocytic infiltration of non-tumor tissues leading to inflammatory responses that cause organ failure. Therefore, we will examine the non-tumor tissue samples for the presence of leukocytes in mice treated with PT-100 and ARI-4175. - Cytokine/chemokine responses to PT-100 are abrogated in IL-1R1 deficient B6. 129S7-Il1r1tm1Imx/J mice (Jackson Laboratory); therefore, if toxicity is due to activity of systemic cytokines/chemokines, MTD should be significantly increased in IL-R1 mutant mice relative to congenic C57BL/6 mice. Therefore, the dose responses of serum G-CSF and CXCL1 cytokines will be compared by ELISA (R&D Systems) and the MTDs of ARI-4175 and PT-100 in B6.129S7-Il1r1tm1Imx/J versus C57BL/6 control mice. MTDs will be determined in groups of 3 mice treated at increasing dose levels. G-CSF and CXCL-1 levels will be determined in serum sampled at 3 and 8 hours after compound administration. If IL-1R1 deficient mice are resistance to toxicity, and if histopathology in
Experiment 6 reveals leukocytic infiltration of non-tumor tissue, IL-1R1 deficient and sufficient mice will be compared histologically to determine if toxicity is related to inflammatory disruption of organ function. - Cetuximab (CTX) is an effective therapeutic agent in a number of malignancies. Current data indicate that about 40% of colorectal cancer patients bearing mutated K-ras do not benefit from this agent. A possible mechanism of the antitumor effect of cetuximab is mediated through antibody-dependent cell-mediated cytotoxicity (ADCC). This study investigated the potential of activity of ARI-4175, in the treatment of K-ras mutant colorectal cancer xenografts as a single agent or in combination with cetuximab.
- The effect of ARI-4175 alone or in combination with cetuximab was evaluated both in vitro and in vivo. In vitro, the proliferation of K-ras mutant colon cancer cell lines DLD-1 and HCT-116 was detected after three days of culture in the medium containing various concentrations of ARI-4175 or cetuximab (
FIG. 10 ). ARI-4175 (10 nM-200 μM) alone or in combination with cetuximab did not show significant cytotoxicity on either DLD-1 or HCT-116 in cell culture (FIG. 10 ). In vivo, nude mice bearing DLD-1 or HCT-116 xenograft tumors were randomly divided into four groups, control, ARI-4175 alone, cetuximab alone and ARI-4175 plus cetuximab. ARI-4175 was administered orally at 100 g, q.d or b.i.d and cetuximab was injected intraperitoneally at 200 μg per week. Tumor measurements were conducted twice a week. In mice growth of both DLD-1 and HCT-116 tumors were significantly blocked by the application of ARI-4175 in a dose-dependent manner (FIGS. 13A and 13B ). The combination of ARI-4175 with cetuximab led to a further decrease in tumor size although not statistically significant, probably due to lower number of animals. Cetuximab alone did not show any therapeutic effect on HCT-116 xenograft but did have moderate efficacy on DLD-1 tumors. - As shown in
FIG. 16 , female C57BL/6 mice were challenged subcutaneously with 1×106 MB49. Mice were orally gavaged on days 3-7 and 10-14. Tumor volume was monitored by caliper measurements. At a 20 μg dose, both PT-100 and ARI-4175 induce anti-tumor activity. ARI-4175 dosing at 200 μg induced full regression in 5 of 5 mice whereas PT-100 was toxic at the same dose. - Despite the small differences in chemical structure between PT-100 and ARI-4175, there are unexpectedly large differences in the pharmacokinetic (PK) profile of the two compounds. In particular, the toxicity of ARI-4175 is much lower.
- All of the U.S. patents and U.S. patent application publications cited herein are hereby incorporated by reference.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (92)
1. A method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
2. The method of claim 1 , wherein said compound is not Val-boroPro.
3. The method of claim 1 or 2 , wherein said compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
4. The method of claim 1 , 2 , or 3 , wherein the cancer is selected from the group consisting of basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, CNS cancer, colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, intra-epithelial neoplasm, kidney cancer, larynx cancer, leukemia, acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, melanoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, renal cancer, cancer of the respiratory system, sarcoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, and cancer of the urinary system.
5. The method of claim 1 , 2 , or 3 , wherein the cancer is selected from the group consisting of prostate cancer, colorectal cancer, multiple myeloma, and non-small cell lung cancer.
6. The method of claim 1 , 2 , or 3 , wherein the cancer is selected from lung cancer, colorectal cancer, breast cancer, pancreatic cancer and prostate cancer.
7. The method of claim 1 , 2 , or 3 , wherein the cancer is lung cancer.
8. The method of claim 7 , wherein the cancer is non-small cell lung cancer.
9. The method of claim 1 , 2 , or 3 , wherein the cancer is colorectal cancer.
10. The method of claim 1 , 2 , or 3 , wherein the cancer is breast cancer.
11. The method of claim 1 , 2 , or 3 , wherein the cancer is pancreatic cancer.
12. The method of claim 1 , 2 , or 3 , wherein the cancer is prostate cancer.
13. The method of any one of the preceding claims, wherein the cancer is metastatic.
14. The method of any one of the preceding claims, further comprising co-administering to the mammal a therapeutically effective amount of tumor-primed T-cells.
15. The method of claim 14 , wherein said tumor-primed T-cells are administered prior to said administration of the compound.
16. The method of claim 14 , wherein said tumor-primed T-cells are administered subsequent to said administration of the compound.
17. The method of claim 14 , wherein said tumor-primed T-cells are administered concurrently to said administration of the compound.
18. The method of any one of claims 1 -13 , further comprising co-administering to the mammal a therapeutically effective amount of an orally active tumor antigen.
19. The method of any one of claims 1 -13 , further comprising co-administering to the mammal a therapeutically effective amount of a dendritic cell vaccine.
20. The method of any one of the preceding claims, further comprising administration of an adjuvant.
21. The method of any one of claims 1 -13 , further comprising treating the mammal with a second therapy selected from the group consisting of surgery, radiation and chemotherapy.
22. The method of claim 21 , wherein the second therapy is surgery.
23. The method of claim 21 , wherein the second therapy is radiation.
24. The method of claim 21 , wherein the second therapy is chemotherapy.
25. The method of claim 24 , wherein the chemotherapy is selected from the group consisting of ipilimumab, vemurafenib, GDC-0879, PLX-4720, aldesleukin, asparaginase, bleomycin sulfate, carboplatin, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin hydrochloride, docetaxel, doxorubicin, doxorubicin hydrochloride, epirubicin hydrochloride, etoposide, etoposide phosphate, floxuridine, fludarabine, fluorouracil, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, interferons, interferon-α2a, interferon-α2b, interferon-αn3, interferon-α1b, interleukins, irinotecan, mechlorethamine hydrochloride, melphalan, mercatopurine, methotrexate, methotrexate sodium, mitomycin, mitoxantrone, paclitaxel, pegaspargase, pentostatin, prednisone, profimer sodium, procabazine hydrochloride, taxol, taxotere, teniposide, topotecan hydrochloride, vinblastine sulfate, vincristine sulfate and vinorelbine tartrate.
26. The method of claim 24 , wherein the chemotherapy is selected from the group consisting of bleomycin sulfate, carboplatin, cisplatin, docetaxel, doxorubicin, doxorubicin hydrochloride, fluorouracil, gemcitabine, gemcitabine hydrochloride, methotrexate, methotrexate sodium, paclitaxel, taxol, taxotere, vinblastine sulfate and vincristine sulfate.
27. The method of claim 24 , wherein the chemotherapy is a dipeptidylpeptidase IV inhibitor.
28. The method of claim 24 , wherein the chemotherapy is a FAP-activated chemotherapeutic, a FAP-activated dipeptidylpeptidase IV inhibitor, or a FAP-activated proteasome inhibitor.
29. The method of claim 24 , wherein the chemotherapy is a FAP-activated proteasome inhibitor.
30. The method of claim 24 , wherein the chemotherapy is an antibody.
31. The method of claim 30 , wherein the antibody is selected from the group consisting of trastuzamab, cetuximab, bevacizumab, and rituximab.
32. A method of increasing antitumor immunity in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
33. The method of claim 32 , wherein said compound is not Val-boroPro.
34. The method of claim 32 or 33 , wherein said compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
35. The method of claim 32 , 33 , or 34 , wherein said antitumor immunity is increased for tumors selected from the group consisting of lung tumors, lymphomas, breast tumors, colorectal tumors, thyroid tumors, uterine tumors, pancreatic tumors, prostate tumors, skin tumors, kidney tumors, liver tumors and brain tumors.
36. The method of claim 32 , 33 , or 34 , wherein said antitumor immunity is increased for tumors selected from the group consisting of lung tumors, breast tumors, colorectal tumors, pancreatic tumors and prostate tumors.
37. The method of any one of claims 32 -36 , wherein the antitumor immunity comprises antibody-dependent cell-mediated cytotoxicity.
38. A method of stimulating or enhancing an immune response in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
39. The method of claim 38 , wherein said compound is not Val-boroPro.
40. The method of claim 38 or 39 , wherein said compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
41. The method of claim 38 , 39 , or 40 , wherein said immune response is stimulated.
42. The method of claim 38 , 39 , or 40 , wherein said immune response is enhanced.
43. The method of any one of claims 38 -42 , wherein the immune response comprises antibody-dependent cell-mediated cytotoxicity.
44. The method of any one of claims 38 -43 , wherein the mammal has cancer or is at risk of developing cancer.
45. The method of any one of claims 38 -43 , wherein said mammal is in remission of cancer.
46. The method of any one of claims 38 -43 , wherein said mammal has a refractory or resistant cancer.
47. A method of treating a condition characterized by abnormal cell proliferation, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
48. The method of claim 47 , wherein said compound is not Val-boroPro.
49. The method of claim 47 or 48 , wherein said compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
50. The method of claim 47 , 48 , or 49 , wherein the abnormal cell proliferation is cancer, a blood vessel proliferative disorder or a fibrotic disorder.
51. The method of claim 47 , 48 , or 49 , wherein the abnormal cell proliferation is abnormal angiogenesis.
52. A method of increasing cytokine and/or chemokine production in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases.
53. The method of claim 52 , wherein said compound is not Val-boroPro.
54. The method of claim 52 or 53 , wherein said compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
55. A method of stimulating or enhancing production of T-cells in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases, wherein said T-cells recognize an antigen on a malignant cell.
56. The method of claim 55 , wherein said compound is not Val-boroPro.
57. The method of claim 55 or 56 , wherein said compound induces the production of a cytokine selected from the group consisting of GCSF and CXCL1.
58. The method of claim 55 , 56 , or 57 , wherein said production of T-cells is stimulated.
59. The method of claim 55 , 56 , or 57 , wherein said production of T-cells is enhanced.
60. The method of any one of claims 55 -59 , wherein said malignant cell is a carcinoma, sarcoma, leukemia, lymphoma or myeloma.
61. The method of any one of the preceding claims, wherein the mammal is a primate, canine, equine, feline or bovine.
62. The method of any one of the preceding claims, wherein the mammal is a human.
63. The method of any one of the preceding claims, wherein the compound is administered orally or parenterally.
64. The method of claim 63 , wherein the compound is administered parenterally.
65. The method of claim 63 , wherein the compound is administered orally.
66. The method of claim 65 , wherein the compound is administered in a solid dosage form.
67. The method of claim 66 , wherein the solid dosage form is a tablet, capsule or pill.
68. The method of claim 66 , wherein the solid dosage form is a tablet.
69. The method of any one of the preceding claims, wherein the compound is administered in an amount sufficient to stimulate the immune system without dose limiting toxicity.
70. The method of any one of claims 1 -69 , wherein the compound is represented by Formula I:
wherein:
X is B(Y1)(Y2) or CN;
Y1 and Y2 are independently OH, or together with the boron atom to which they are attached represent a group that is hydrolysable to a boronic acid, or together with the boron atom to which they are attached form a 5- to 8-membered ring that is hydrolysable to a boronic acid;
R1 is selected from the group consisting of halogen, lower alkyl, lower alkenyl, lower alkynyl, carbonyl, carboxyl, ester, formate, ketone, thiocarbonyl, thioester, thioacetate, thioformate, amino, acylamino, amido, nitro, sulfate, sulfonate, sulfonamido, —(CH2)m—R7, —(CH2)m—OH, —(CH2)m—O-lower alkyl, —(CH2)m—O-lower alkenyl, —(CH2)n—O—(CH2)m—R7, —(CH2)m—SH, —(CH2)m—S-lower alkyl, —(CH2)m—S-lower alkenyl, or —(CH2)n—S—(CH2)m—R7, azido, cyano, isocyanato, thiocyanato, isothiocyanato, cyanato,
or —C≡C—R8;
R7 represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle;
R8 independently represents hydrogen, —CH3, or —(CH2)n—CH3;
m is 0, 1, 2, 3, 4, 5, or 6;
R2 is a hydrophobic group selected from the group consisting of n-propyl, C4-C8 alkyl, C2-C8alkenyl, C2-C8alkynyl, C3-C8cycloalkyl, C2-C7heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, and side chains of naturally occurring hydrophobic amino acids;
n is 0, 1, or 2; and
q is 0, 1, 2, 3, or 4.
71. The method of claim 70 , wherein q is 0, 1, or 2.
72. The method of claim 70 , wherein q is 0.
73. The method of any one of claims 70 -72 , wherein n is 0.
74. The method of any one of claims 70 -72 , wherein n is 1.
75. The method of any one of claims 70 -72 , wherein n is 2.
76. The method of any one of claims 70 -75 , wherein X is B(Y1)(Y2).
77. The method of any one of claims 70 -75 , wherein X is B(OH)2.
78. The method of claim 70 , wherein n is 1; q is 0; and X is B(OH)2.
79. The method of any one of claims 70 -78 , wherein R2 is selected from the group consisting of t-butyl, isobutyl, pentyl, cyclohexyl, benzyl, or naphthyl.
80. The method of any one of claims 70 -78 , wherein R2 is selected from the group consisting of t-butyl, isobutyl, or pentyl.
81. The method of any one of claims 70 -78 , wherein R2 is t-butyl.
82. The method of any one of claims 70 -78 , wherein R2 is the side chain of a naturally occurring hydrophobic amino acid.
83. The method of any one of claims 70 -78 , wherein R2 is the side chain of leucine, isoleucine, tert-leucine, phenylalanine, or tryptophan.
84. The method of claim 70 , wherein the compound of Formula I is t-butylGly-boroPro.
85. The method of any one of claims 70 -84 , wherein the stereochemical configuration at the carbon bearing X is L.
86. The method of any one of claims 70 -84 , wherein the stereochemical configuration at the carbon bearing X is D.
87. The method of any one of claims 70 -84 , wherein the stereochemical configuration at the carbon bearing R2 is L.
88. The method of any one of claims 70 -84 , wherein the stereochemical configuration at the carbon bearing R2 is D.
89. The method of any one of claims 70 -84 , wherein the stereochemical configuration at the carbon bearing X is L; and the stereochemical configuration at the carbon bearing R2 is L.
90. The method of any one of claims 70 -84 , wherein the stereochemical configuration at the carbon bearing X is L; and the stereochemical configuration at the carbon bearing R2 is D.
91. The method of any one of claims 70 -84 , wherein the stereochemical configuration at the carbon bearing X is D; and the stereochemical configuration at the carbon bearing R2 is L.
92. The method of any one of claims 70 -84 , wherein the stereochemical configuration at the carbon bearing X is D; and the stereochemical configuration at the carbon bearing R2 is D.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/817,754 US20180092933A1 (en) | 2011-11-22 | 2017-11-20 | Small molecule enhancer for dendritic cell cancer vaccines |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161562497P | 2011-11-22 | 2011-11-22 | |
PCT/US2012/065236 WO2013078059A1 (en) | 2011-11-22 | 2012-11-15 | Small molecule enhancer for dendritic cell cancer vaccines |
US201414353408A | 2014-04-22 | 2014-04-22 | |
US14/948,777 US9839646B2 (en) | 2011-11-22 | 2015-11-23 | Small molecule enhancer for dendritic cell cancer vaccines |
US15/817,754 US20180092933A1 (en) | 2011-11-22 | 2017-11-20 | Small molecule enhancer for dendritic cell cancer vaccines |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/948,777 Continuation US9839646B2 (en) | 2011-11-22 | 2015-11-23 | Small molecule enhancer for dendritic cell cancer vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180092933A1 true US20180092933A1 (en) | 2018-04-05 |
Family
ID=48470210
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/353,408 Active US9284337B2 (en) | 2011-11-22 | 2012-11-15 | Small molecule enhancer for dendritic cell cancer vaccines |
US14/948,777 Active US9839646B2 (en) | 2011-11-22 | 2015-11-23 | Small molecule enhancer for dendritic cell cancer vaccines |
US15/817,754 Abandoned US20180092933A1 (en) | 2011-11-22 | 2017-11-20 | Small molecule enhancer for dendritic cell cancer vaccines |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/353,408 Active US9284337B2 (en) | 2011-11-22 | 2012-11-15 | Small molecule enhancer for dendritic cell cancer vaccines |
US14/948,777 Active US9839646B2 (en) | 2011-11-22 | 2015-11-23 | Small molecule enhancer for dendritic cell cancer vaccines |
Country Status (9)
Country | Link |
---|---|
US (3) | US9284337B2 (en) |
EP (2) | EP2782994B1 (en) |
JP (2) | JP6240083B2 (en) |
CN (2) | CN106075450A (en) |
AU (2) | AU2012340887A1 (en) |
CA (1) | CA2856379A1 (en) |
HK (1) | HK1201871A1 (en) |
IL (1) | IL232664A0 (en) |
WO (1) | WO2013078059A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012340887A1 (en) * | 2011-11-22 | 2014-07-03 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
JP2018500299A (en) | 2014-11-25 | 2018-01-11 | バイオエクセル コーポレーション | Use of ubiquitin-proteasome inhibitors for the treatment of tumors associated with neurofibromatosis type 2 |
CA2991628C (en) * | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
US11000521B2 (en) | 2015-08-03 | 2021-05-11 | Institut Pasteur | Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy |
CN109906082A (en) * | 2016-09-07 | 2019-06-18 | 塔夫茨大学信托人 | Use the combined therapy of immune DASH inhibitor and PGE2 antagonist |
EP3571200B8 (en) | 2017-01-17 | 2022-08-03 | HepaRegeniX GmbH | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
WO2018187698A2 (en) * | 2017-04-07 | 2018-10-11 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and pge2 antagonists |
US11559537B2 (en) | 2017-04-07 | 2023-01-24 | Trustees Of Tufts College | Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists |
JP2019208422A (en) * | 2018-06-04 | 2019-12-12 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | Novel recombinant exosome containing hyaluronidase and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6040145A (en) * | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
WO2007005991A1 (en) * | 2005-07-05 | 2007-01-11 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein alpha |
US9284337B2 (en) * | 2011-11-22 | 2016-03-15 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010079669A (en) | 1998-08-21 | 2001-08-22 | 바바라 피. 월너 | Regulation of Substrate Activity |
JP2003500360A (en) * | 1999-05-25 | 2003-01-07 | ポイント セラピューティクス, インコーポレイテッド | Anticancer agents containing boroproline compounds |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
CN100392074C (en) * | 2003-10-15 | 2008-06-04 | 上海海欣生物技术有限公司 | Dendritic cell tumor vaccine and its preparation and use |
US8268880B2 (en) * | 2005-12-19 | 2012-09-18 | Trustees Of Tufts College | Soft protease inhibitors and pro-soft forms thereof |
WO2007123686A2 (en) * | 2006-03-31 | 2007-11-01 | Point Therapeutics, Inc. | Dpp inhibitors and uses thereof |
JP2010523477A (en) * | 2007-03-20 | 2010-07-15 | トラスティーズ オブ タフツ カレッジ | Inhibitors of fibroblast activation protein and methods of using the same |
CN101755045B (en) * | 2007-05-17 | 2014-02-12 | 生物载体株式会社 | Method for production of dendritic cell |
KR101483715B1 (en) * | 2008-01-31 | 2015-01-19 | 큐어백 게엠바하 | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS/ADJUVANTS |
-
2012
- 2012-11-15 AU AU2012340887A patent/AU2012340887A1/en not_active Abandoned
- 2012-11-15 WO PCT/US2012/065236 patent/WO2013078059A1/en active Application Filing
- 2012-11-15 EP EP12850873.6A patent/EP2782994B1/en active Active
- 2012-11-15 CN CN201610493117.7A patent/CN106075450A/en active Pending
- 2012-11-15 JP JP2014543501A patent/JP6240083B2/en active Active
- 2012-11-15 US US14/353,408 patent/US9284337B2/en active Active
- 2012-11-15 EP EP16180971.0A patent/EP3106173A1/en not_active Withdrawn
- 2012-11-15 CA CA2856379A patent/CA2856379A1/en not_active Abandoned
- 2012-11-15 CN CN201280067478.5A patent/CN104039952A/en active Pending
-
2014
- 2014-05-18 IL IL232664A patent/IL232664A0/en unknown
-
2015
- 2015-03-06 HK HK15102280.8A patent/HK1201871A1/en unknown
- 2015-11-23 US US14/948,777 patent/US9839646B2/en active Active
-
2017
- 2017-08-22 JP JP2017159116A patent/JP2017214420A/en active Pending
- 2017-11-20 US US15/817,754 patent/US20180092933A1/en not_active Abandoned
-
2018
- 2018-06-25 AU AU2018204591A patent/AU2018204591A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6040145A (en) * | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
WO2007005991A1 (en) * | 2005-07-05 | 2007-01-11 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein alpha |
US9284337B2 (en) * | 2011-11-22 | 2016-03-15 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
US9839646B2 (en) * | 2011-11-22 | 2017-12-12 | Trustees Of Tufts College | Small molecule enhancer for dendritic cell cancer vaccines |
Also Published As
Publication number | Publication date |
---|---|
EP3106173A1 (en) | 2016-12-21 |
JP6240083B2 (en) | 2017-11-29 |
EP2782994A1 (en) | 2014-10-01 |
US20160310513A1 (en) | 2016-10-27 |
CA2856379A1 (en) | 2013-05-30 |
WO2013078059A1 (en) | 2013-05-30 |
HK1201871A1 (en) | 2015-09-11 |
JP2014533727A (en) | 2014-12-15 |
US9284337B2 (en) | 2016-03-15 |
CN106075450A (en) | 2016-11-09 |
EP2782994B1 (en) | 2017-05-10 |
JP2017214420A (en) | 2017-12-07 |
EP2782994A4 (en) | 2015-07-15 |
AU2018204591A1 (en) | 2018-07-12 |
AU2012340887A1 (en) | 2014-07-03 |
CN104039952A (en) | 2014-09-10 |
US9839646B2 (en) | 2017-12-12 |
IL232664A0 (en) | 2014-07-31 |
US20140271725A1 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9839646B2 (en) | Small molecule enhancer for dendritic cell cancer vaccines | |
US20210170022A1 (en) | Combination drug including tlr7 agonist | |
Ghiringhelli et al. | Enhancing the anticancer effects of 5-fluorouracil: current challenges and future perspectives | |
WO2016204193A1 (en) | Anticancer agent | |
WO2019072220A1 (en) | Use of pd-1 antibody combined with epigenetic regulator in preparation of drug for treating tumors | |
EP3609878B1 (en) | Compounds, composition and uses thereof for treating cancer | |
WO2018053270A1 (en) | Modified natural killer cells for the treatment of cancer | |
US20220047597A1 (en) | Madrasin-derivative compounds, composition and uses thereof for treating cancer | |
US20220313724A1 (en) | Compositions for intratumoral administration and related methods | |
Yao et al. | It’s high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer | |
CN116322771A (en) | Novel use of tubercle bacillus extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TRUSTEES OF TUFTS COLLEGE, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BACHOVCHIN, WILLIAM W.;REEL/FRAME:044971/0754 Effective date: 20140430 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |